Novel insights into the physiological significance of the human P2Y 11 receptor (Alanine-87-Threonine) single nucleotide polymorphism -possible connection to inflammatory processes Michael Haas, Georg Reiser (Magdeburg, Germany) 
Unexpexted roles of P2Y receptors in heart and bone Strains of knockout mice are now available for all P2Y receptor subtypes. Their phenotyping has confirmed hypotheses on the role of these receptors in physiopathology, such as the cooperation of P2Y 1 and P2Y 12 receptors in the control of platelet aggregation. But it has also revealed unexpected roles, like the involvement of the liver P2Y 13 receptors in reverse cholesterol transport [Fabre AC. et al. P2Y 13 receptor is critical for reverse cholesterol transport. Hepatology, 52: 1477 Hepatology, 52: -1483 Hepatology, 52: , 2010 . Recent studies in our laboratory have uncovered the role of the P2Y 4 receptor in cardiac [Fabre et al., 2010] development, function and pathology. This research started with the serendipitous observation that P2Y 4 -deficient mice have a smaller heart. The P2Y 4 receptor is expressed on cardiac microvascular endothelial cells and controls the early post-natal angiogenesis that leads to cardiomyocyte hyperplasia [Horckmans M. et al. P2Y 4 nucleotide receptor: a novel actor in angiogenesis and cardiac development. Angiogenesis, 15: 349-360, 2012] . The smaller heart of P2Y 4 -deficient mice is associated with a hemodynamic defect leading to decreased physical exercise capacity [Horckmans M. et al. Gene deletion of P2Y 4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise. Am J PhysiolHeart and Circulation, 303: H835-H843, 2012] . Interestingly the P2Y 4 -deficient mice are protected against myocardial infarction, with a decrease in infarct size and fibrosis. The lower expression of adhesion molecules on microvascular endothelial cells resulting in a decreased infiltration of neutrophils plays a major role in this protection. Bone metabolism is disturbed in P2Y 13 -deficient mice, with a decrease in both bone formation and bone resorption [Wang N. et al. Reduced bone turnover in mice lacking the P2Y 13 receptor. Molecular Endocrinology, 26: 142-152, 2012] . As a consequence these mice are protected against ovariectomy-induced bone loss. The decreased bone formation can be explained by a smaller number of osteoblasts. Indeed bone marrow mesenchymal stem cells from P2Y 13 −/− mice differentiate less into osteoblasts and more into adipocytes [Biver G. et al. Role of the P2Y 13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Stem Cells, doi: 10.1002/stem.1411]. These studies on knockout mice suggest thus that P2Y 4 and P2Y 13 receptors might be valuable targets for the treatment of myocardial infarction and osteoporosis.
ORAL COMMUNICATIONS

ABSTRACTS SYMPOSIUM 1 PURINES AND INFLAMMATION
The P2X7 receptor: A cell sensor of danger Francesco Di Virgilio Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy
Inflammation is the key pathophysiological response triggered by noxious agents in multicellular organisms. Virtually no perturbation in body homeostasis can occur without generating a local or systemic inflammatory response. Inflammation is intimately intertwined with innate and adaptive immunity, and therefore deeply involved in the pathogenesis of immune-mediated diseases. In order to decipher the mechanisms underlying the different forms of inflammation (not only typical acute and chronic inflammation but also the different presentations that both acute and chronic inflammation may have), and understand the different facets of the immune response (e.g. protective immunity, allergy and hypersensitivity, tolerance, suppression) we need to identify and dissect the events occurring during the initial few minutes following an injury or the encounter with a pathogen. This rather short interval is crucial for all the following events and for the final outcome. Key factors determining the progression and the presentation of inflammation are PAMPs/MAMPs (Pathogen-Associated Molecular Patterns/Microbe-Associated Molecular Patterns), DAMPs (Damage-Associated Molecular Patterns), PRR (Pattern Recognition Receptors), cells of innate and adaptive immunity, and the inflammasomes. DAMPs are molecules that are normally absent from the extracellular environment under healthy conditions, but that are released when a foreign microorganism enters and multiplies within our body (infection) or as a consequence of tissue injury (sterile inflammation). In this context, extracellular ATP is a perfect DAMP, and ATP receptors the perfect sensors for DAMPs. Thanks to its unusual coupling to a multiplicity of pro-inflammatory responses, P2X7 stands out for its ability to link increases in the extracellular ATP concentration to the early phases of inflammation. I will discuss recent evidence that lead to identification of the molecular pathways coupling P2X7 to ignition of inflammation [Di Virgilio F (2013) The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev 65:872-905].
Novel insights into the physiological significance of the human P2Y 11 receptor (Alanine-87-Threonine) single nucleotide polymorphism -possible connection to inflammatory processes Michael Haas, Georg Reiser Institut für Neurobiochemie, Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg, Germany
The Alanine-87-Threonine single nucleotide polymorphism (SNP) of the human P2Y 11 receptor was found to be linked with an increased risk for acute myocardial infarction (AMI) and elevated levels of C-reactive protein (Amisten et. al 2007) . An impact on inflammatory processes was assumed, but the physiological significance of this SNP for the P2Y 11 receptor function remained unclear. In our study, we found a decreased nucleotide-dependent excitability of the human P2Y 11 receptor in HEK293 cells, which endogenously express the P2Y 1 receptor. Differences were found for intracellular calcium signalling and cAMP accumulation. The impact on intracellular calcium signalling could be reproduced in 1321N1 astrocytoma cells co-expressing the P2Y 1 and P2Y 11 A87T receptors but not in cells expressing only the P2Y 11 A87T receptor. Furthermore, the internalization of the P2Y 11 receptor in HEK293 cells, mediated through interaction with the P2Y 1 receptor, could not be observed for the P2Y 11 A87T receptor. Therefore, we suggest that the Ala-87-Thr SNP has an impact on the function of the P2Y 1 -P2Y 11 -hetero-oligomer. The P2Y 1 and P2Y 11 receptors can be found in dendritic cells, which undergo an ATP-dependent maturation process and can act as promoter for inflammation. Dendritic cells can also be found in atherosclerotic plaques, a major risk factor for AMI. Our findings of a physiological significance of the Ala-87-Thr SNP strengthen the concept of a connection of P2Y 11 receptors physiology to inflammatory processes in human tissues.
The purinergic P2X7 receptor in Behçet's disease monocytes: Expression, function and modulation by TNFα Monocytes were isolated from 18 BD patients and 17 healthy controls matched for age and sex. P2X7r expression (flow-cytometry), and function (cytosolic free Ca 2+ flux measurements in single-cell fluorescent microscopy, and IL-1β release [ELISA] ) were studied. Moreover, the effect of TNFα on P2X7r expression and function was evaluated in monocytes from healthy controls. In BD monocytes, an increased P2X7r expression and Ca 2+ permeability induced by the selective P2X7r agonist 2′-3′-O-(4-benzoylbenzoyl)ATP (BzATP) were observed. Moreover, IL-1β release from lipopolysaccharides-primed monocytes stimulated with BzATP was markedly higher in BD patients than in controls. TNFα-incubated monocytes from healthy subjects almost reproduced the findings observed in BD patients, as demonstrated by the significant increase in P2X7r expression and BzATP-induced Ca2+ intake. Our results provide evidence that in monocytes from BD patients both the expression and function of the P2X7r are increased with respect to healthy controls as the possible result, at least in part, of a positive modulating effect of TNFα on the receptor. These data indicate P2X7r as a new potential therapeutic target for the control of BD, further supporting the rationale for the use of anti-TNFα drugs in the treatment of the disease.
SYMPOSIUM 2 MEDICINAL CHEMISTRY OF PURINE RECEPTORS
Recent progress in the development of ligands for purinergic targets Christa E. Müller PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
Membrane receptors activated by purines are subdivided into three distinct families: (i) purine and/or pyrimidine nucleotide ("P2 receptors ") receptors, further divided into G protein-coupled P2Y receptors (P2Y 1, 2, 4, 6, 11, 12, 13, 14 ) , and homo-or heterotrimeric ligandgated ion channels termed P2X receptors (subunits: P2X1-7); (ii) adenosine or P1 receptors (four subtypes: A 1 , A 2A , A 2B , A 3 ), and (iii) P0 receptors activated by the nucleobase adenine. Purinergic signalling is modulated by ecto nucleotidases , which are often coexpressed with purine receptors catalyzing the degradation of extracellular nucleotides [Zimmermann H, Zebisch M Med. Chem. 2013, in press] . This talk will focus on the development of (1) A 2A adenosine receptor antagonists with ancillary monoamine oxidase B (MAO-B) inhibitory activity ("dual inhibitors") for the treatment of neurodegenerative diseases; (2) P2X4 receptor antagonists for the alleviating neuropathic pain, and (3) ecto-5′-nucleotidase inhibitors as potential anti-metastatic and anti-cancer drugs. Adenosine is released from metabolically active cells and is generated by the degradation of released ATP. The action of adenosine occurs through the stimulation of the purinergic receptors that were classified as P1 receptors, whereas the receptors activated by nucleotides like adenosine 5′ triphosphate (ATP) were classified as P2 receptors [Fredholm, B. B.; Pharmacol Rev., 2001, 53, 527-552] . P1 Receptors: A 1 adenosine receptors. In this lecture we will describe the synthesis and biological evaluation of a novel series of 2-amino-3-aroylthiophenes, with variable modifications at the 4-and 5-position [Baraldi, P. G.; Romagnoli, R.; Pavani, M. G.; Nunez, M. C.; Aghazadeh Tabrizi, M.; Shryock, J. C.; Leung, E.; Moorman, A. R.; Uluoglu,|C., Iannotta, V.; Merighi, S.; Borea, P.A. J. Med. Chem. 2003, 46, 794-809] A 2A adenosine receptors. From the initial work on SCH 58261, we have prepared several compounds series, bearing substitution at the pyrazole nitrogen, such as SCH 63390 and their oxygenated derivatives [Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Borioni, A.; Viziano, M.; Dionisotti, S.; Ongini, E. Curr. Med. Chem. 1995, 2, 707-722] . A 3 adenosine receptors. In the past years we have synthesized an extensive series of pyrazolotriazolopyrimidines bearing different substitutions on the phenylcarbamoyl moieties at the N5 position, being highly potent and selective human A 3 adenosine receptor antagonists [Baraldi, P. G A 2B adenosine receptors. In this lecture will be presented medicinal chemistry studies on the synthesis and biological evaluation of 8-heterocyclesubstituted xanthines as potent and selective A 2B adenosine receptor antagonists [Baraldi, P. G.; Tabrizi, M. A.; Gessi, S.; Borea, P. A. Chem. Rev. 2008, 108, 238-263] .
Multiple signaling pathways of the human A 2B adenosine receptor: Activation by structurally diverse agonists Marthe Koussemou, Kristina Lorenz, Sonja Kachler, Karl-Norbert Klotz Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Str. 9D-97078 Würzburg, Germany
The P1 purinergic receptors comprise a family of four subtypes termed A 1 , A 2A , A 2B and A 3 . The classical signaling pathways of the A 1 and A 3 subtypes is Gi protein-mediated inhibition of adenylyl cyclase whereas the A 2 subtypes mediate activation of adenylyl cyclase via G s . In the past it was found that the A 2B receptor may also trigger a Ca 2+ signal. Such a response was also observed in the estrogen-receptor negative breast cancer cell line MDA-MB-231 which is expressing high levels of A 2B adenosine receptors as the sole adenosine receptor subtype. In these cells, the A 2B -mediated rise in cytosolic Ca 2+ was dependent on phospholipase C (PLC) activity and is thus most likely linked to activation of G q . While attempting to identify an A 2B -dependent stimulation of MAPK signaling we found a very high basal ERK 1/2 phosphorylation which could not be further increased by known stimuli like FCS or ATP. Instead, we discovered that stimulation of A 2B adenosine receptors results in the inhibition of ERK 1/2 phosphorylation in MDA-MB-231 cells. The availability of a panel of structurally diverse agonists led us to investigate whether different ligands may activate these responses with different efficacies or potencies. The non-selective agonist NECA (5′-N-ethylcarboxamidoadenosine) was used as a prototypical agonist characterized by only a minimal change to the structure of the natural agonist adenosine in 5′-position affording metabolic stability. Another non-selective agonist with more significant changes to the adenosine structure was PHPNECA (2-(3-hydroxy-3-phenyl)propyn-1-yl-NECA), bearing a 2-substitution. DPA23 (N 6 -{4-[(phenylcarbamoyl)-methoxy]-phenyl}-NECA) is an N 6 -substituted agonist showing A 2B -selectivity. Additional agonists combining 2-and N 6 -substituents or ligands without an adenosine structure were also tested. Although adenylyl cyclase activation and the Ca 2+ signal were mediated by different G proteins all agonists showed similar EC 50 values for these responses. In contrast, inhibition of ERK 1/2 phosphorylation generally occurred at lower concentrations suggesting this signal to be the preferred pathway in MDA-MB-231 cells. Stimulation of A 2B adenosine receptors might therefore play a role in the control of proliferation of these cells. The potent inhibition of ERK 1/2 phosphorylation via A 2B receptors suggests that this subtype might be a useful target for co-therapies in cancer treatment. A number of extracellular nucleotidases are involved in the conversion of nucleotides in purinergic signalling [Zimmermann, H., Zebisch, M., Sträter, N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signalling (2012) 8:437-502]. Ecto-5′-nucleotidase (eN, CD73) catalyses the hydrolysis of AMP to adenosine. In addition to the receptors for extracellular nucleotides and nucleosides, also the ecto-nucleotidases have been recognized as pharmaceutical targets to interfere with purinergic signaling pathways. Specific inhibitors would not only be valuable tools in biopharmaceutical fundamental research. They would also constitute potential clinical therapeutics. CD73 has raised particular interest recently as a target for antitumor drugs since the enzyme is a major source of immunosuppressive adenosine and it is overexpressed in certain tumor types. For the production of recombinant e5NT an E.coli expression system was established including refolding procedures and subsequent purification. Different variants were expressed and tested for their activity as well as suitability for crystallization. So far, we obtained three crystal forms [Knapp, K., Zebisch, M., Pippel, J., El-Tayeb, A., Müller, C. E. and Sträter, N. Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling. Structure (2012) 20: 2161-2173]. In two crystal forms the enzyme is in an open conformation. One of these is suitable for inhibitor binding studies to the open state and we characterized different co-crystal structures with synthetic inhibitors. One crystal form contains CD73 in the closed state. The two forms differ by a large domain rotation of~100°. The closed form is only obtained in the presence of AMPCP and the non-hydrolyzable ADP analog cannot be replaced for other inhibitors. Only derivates of AMPCP do also induce this crystal form and the binding mode of these compounds to the closed state can be studied. Interestingly, relatively potent inhibitors can be obtained based on the AMPCP scaffold.
Structural studies on inhibitor binding to human CD73
The publication of crystal structures of zebra fish P2X4 in apo and ATP-bound form [Kawate, T.; Michel, J.C.; Birdsong, W.T.; Gouaux, E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009, 460, 592-98; Hattori, M.; Gouaux, E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 2012, 485, 207-12] represents a critical step for the analysis of receptor structure, the interpretation of mutagenesis data, and the depiction of ligand binding and receptor activation mechanism. In addition, the availability of ATP-competitive ligands presenting selectivity for P2X receptor subtypes provides useful information for the design of new potent and selective ligands with possibly improved pharmacokinetic profile, aimed at obtaining new drugs. Molecular modeling studies were performed to develop the structural models of the human P2X receptors in apo and ATP-bound form. These models allowed to analyse the role of some non-conserved residues at ATP binding site entrance and to study their interaction with some non-specific or subtype selective ligands.
State-dependent conformations of the ATP-binding site of the P2X2 receptor are stabilized by salt bridge networks The release of the Glu167/Arg290 salt bridge during ATP activation of the P2X2 receptor enables Arg290 to undergo a strong ionic interaction with a γ-phosphate oxygen of ATP. This switching of the electrostatic interaction of Arg290 from Glu167 to ATP seems to represent a crucial early event in the gating of the rP2X2 receptor by linking the ionic coordination of ATP within the ATP binding pocket with a simultaneous destabilization of the closedstate of the rP2X2 by the ATP-induced breaking of the Glu167/Arg290 salt bridge. The zfP2X4-based homology models of the rP2X2 receptor further predicted Arg290 to be in the close vicinity to the acidic residues Asp82, Glu84 or Glu85, suggesting that additional state-dependent and structurally important ionic interactions exist. Disulfide trapping and biochemical analysis of substituted cysteine residues confirmed that Arg290 is indeed in the close proximity of <4.5 Å to Asp82, Glu84 and Glu85 when the rP2X2 receptor is in the closed state. In addition, functional analysis of mutants resulting in charge reversal, charge swapping and charge neutralization suggests that Arg290 and Glu84 are electrostatically coupled. Whether this additional salt bridge between Arg290 and Glu84 also serves to stabilize the closed state of the rP2X2 receptor and plays also a role in the closed-to-open transition of the channel has to be determined. This work was supported by Deutsche Forschungsgemeinschaft Grants Schm536/8-2 and HA6095/1-1.
Funtcion of the second transmembrane domain of the human P2X7 receptor The second transmembrane domain (TM2) of P2X receptors is believed to line the pore of these ATP-activated cation channels. Here, we applied cysteine scanning to investigate the role of TM2 residues in the permeation and gating of the human P2X7 receptor (hP2X7R). Following heterologous expression of the hP2X7R cysteine substitution mutants in Xenopus oocytes, their function was measured by voltage-clamp in the whole-cell mode and by single-channel voltage-clamp in the outside-out configuration before and after application of methanethiosulfonate (MTS) reagents, which can covalently react with the substituted cysteines. Furthermore, we checked if the hP2X7R cysteine substitution mutants expressed in Xenopus oocytes could be labeled by extracellularly applied sulfo-Cy5-maleimide. At the putative extracellular end of the hP2X7R TM2 domain, we found cysteine substitution mutants which could be labeled by the fluorescent Cy5 dye, but were not functionally affected by the application of MTS reagents, i.e. the ATP-induced currents were not affected by MTS administration. This indicates that the corresponding amino acid residues are extracellularly accessible, but are neither involved in the gating nor in the permeation of the ion channel. One hP2X7R mutant (S342C) could be Cy5-labeled and the ATP-induced current was blocked by the cationic 2-aminoethyl methanethiosulfonate (MTSEA) pointing to an involvement of S342 in ion permeation or to a stabilization of the closed state of the channel. Several other cysteine mutants were both labeled by the Cy5 dye and exhibited increased ATP-induced currents after MTSEA application. This MTSEA-dependent current increase was mainly due to an increase of the channel's open probability indicating that the corresponding amino acid residues are not involved in ion permeation but rather in P2X7R channel gating and that cysteine substitution destabilizes the closed state of the ion channel. The structure-function relationship of the TM2 domain of the hP2X7R is discussed using a hP2X7R homology model based on the published X-ray structures of the zebrafish-P2X4 receptor.
SYMPOSIUM 4 PURINE ACTIVITY ON PROGENITOR BRAIN CELLS
Purinergic signaling in differentation and neural phenotype determination Henning Ulrich Depto de Bioquímica, Instituto de Química, Univ. de São Paulo, São Paulo, Brazil Stem cells are intensively studied regarding their differentiation capacity and their possible therapeutic applications in various pathological conditions, since these cells can differentiate and substitute damaged tissue improving function. Pluripotent stem cells are distinguished by their ability to proliferate indefinitely in vitro and yield all cell types of an adult organism. Purinergic receptors, mainly P2Y subtypes, have been implicated to participate in the regulation of ES cell proliferation; however, little is known about the functions of other components of the purinergic system. We have used the pluripotent murine ES-E14TG2a embryonic (ES) stem and P19 embryonal carcinoma (EC) cell lines as in vitro models for studying the effects of purinergic receptors on proliferation and differentiation induction. P2X2, P2X5 and P2X7 subunits were highly expressed in undifferentiated ES cells. Purinergic receptor activation by Bz-ATP increased the number of cells at S phase together of cells being in G2/M, pointing at purinergic receptor participation in regulation of proliferation. The cells maintained their pluripotent state with Bz-ATP or Kn-62 (P2X7 receptor antagonist) treatment. Activation of purinergic ionotropic receptors by Bz-ATP enhanced gene expression of stage-specific antigen (SSEA)-1, indicating that P2X7 and possibly other ionotropic purinergic receptor activities were involved in the onset of neuroectodermal differentiation. P2X7 receptor expression was down-regulated when ES cells were induced by retinoic acid to differentiate into neurons. Differentiation of pluripotent into neural progenitor cells was accelerated in the presence of Kn-62, as determined by enhanced nestin and doublecortin expression. Mechanisms of proliferation and differentiation induction of neural progenitor cells were further studied in detail in pluripotent P19 embryonal cells. P2Y2 and P2X2 receptors triggered neuronal differentiation of P19 progenitor cells, while P2X7 receptors participated in proliferation stimulation. Down-regulation of P2X2 or P2X7 receptor expression along differentiation by stable RNA interference resulted in inhibition of neurogenesis or gliogenesis, respectively. Moreover, P2Y2 and P2X2 receptor activities participated in neurotransmitter receptor specification of differentiating neurons. Our work defines applications of purinergic agonists for maintenance and differentiation of ES cell cultures with possible applications in brain tissue repair. The subventricular zone (SVZ) of the lateral ventricles is one of the two neurogenic regions persisting in the adult brain. Here, GFAP + precursors (Type B cells) give raise to transit-amplifying Mash1+ Type C cells, which eventually further differentiate to doublecortin + neuroblasts (Type A cells). It is now emerging that brain injuries boost neurogenesis in the adult SVZ, also through action on surrounding parenchyma or niche cells. Nevertheless, very few newborn neurons survive and integrate in the damaged areas, suggesting a non-permissive environment. Thus, understanding the pro-or antineurogenic activity of the various molecules composing the extracellular milieu of the neurogenic niche would greatly help designing appropriate pharmacological approaches to promote neurogenesis while reducing inhibitory signals. In pathological conditions, the concentrations of extracellular nucleotides (eNTs) raise several folds, and contribute to reactive astrogliosis [Abbracchio & Ceruti, PUSI 2:595, 2006] . Among their multiple functions in brain parenchima, astrocytes are also key components of the neurogenic niche, and regulate neural stem cells (NSC) proliferation and differentiation. Moreover, also eNTs could directly modulate SVZ cells, possibly through the G protein-coupled P2Y 1 nucleotide receptor [Mishra et al., Development, 33:675, 2006; Grimm et al., J Cell Sci 122:2524 , 2009 , although very few data are available especially in vivo.
In the present study, we tested the ability of the stable P2Y 1 agonist ADPβS to control adult NSC activities, with a focus on the possible effects exerted by reactive astrocytes. ADPβS administration in the lateral ventricle of adult mice caused both reactive astrogliosis in the brain parenchyma and activation of SVZ progenitors. Indeed, proliferation of GFAP + NSCs increased, leading to a significant expansion of the population of transit-amplifying Mash1+ progenitors and doublecortin + neuroblasts in the SVZ. Lineage tracing experiments further demonstrated that ADPβS promoted GLAST + progenitor proliferation, and sustained their progression towards the generation of rapidly dividing progenitors. Data were fully confirmed in vitro by the neurosphere assay, where ADPβS stimulated the differentiation of undissociated NS towards GFAP + astrocytes, and β-IIITub + neurons. To test whether ADPβS was acting directly on NSCs only or whether reactive astrocytes were involved, we grew NS in the conditioned media derived from Control astrocytic cultures or from astrocytes cultured in presence of ADPβS. Both astrocyte-conditioned medium reduced the number and size of primary NS with respect to control neurosphere medium. Notably, a significant enhancement in SVZ progenitor proliferation was observed when SVZ cells, initially grown in the supernatant of astrocytes exposed to ADPβS, were then shifted to normal medium. This suggests that ADPβS stimulates the release of yet-to-be identified mediator(s) whose removal boosted proliferation of SVZ cells. Our preliminary results from an ELISA assay suggest that IL-10 could likely play a role in this effect. Taken together our results strengthen evidence that purinergic system crucially regulates SVZ progenitors, both directly and through the involvement of reactive astrocytes. The pharmacological modulation of the purinergic system could therefore represent a promising and innovative approach to exploit the intrinsic ability of the adult brain to regenerate in acute and chronic neurodegenerative disorders.
Apoptotic/necrotic P2X7 receptors at neural proginator cells of the mouse brain ) in the bath medium. The Bz-ATP-induced currents reversed their polarity near 0 mV; in NPCs prepared from P2X7 −/− mice, Bz-ATP failed to elicit membrane currents. The general P2X/P2Y receptor antagonist PPADS and the P2X7 selective antagonists Brilliant Blue G and A-438079 strongly depressed the effect of Bz-ATP. Long-lasting application of Bz-ATP induced an initial current, which slowly increased to a steady-state response. In combination with the determination of YO-PRO uptake, these experiments suggest the dilation of a receptor-channel and/or the recruitment of a dye-uptake pathway. Ca 2+ -imaging by means of Fura-2 revealed that in a Mg 2+ -deficient bath medium Bz-ATP causes [Ca 2+ ] i transients fully depending on the presence of external Ca
2+
. The MTT test documented a concentration-dependent decrease in cell viability by Bz-ATP treatment. Correspondingly, Bz-ATP led to an increase in active caspase 3 immunoreactivity, indicating a P2X7-controlled apoptosis. In acute SVZ brain slices of transgenic Tg(nestin/EGFP) mice, patchclamp recordings identified P2X7Rs at NPCs with pharmacological properties identical to those of their cultured counterparts. Further, NPCs in the dentate gyrus (DG) of hippocampal brain slices of Tg(nestin/EGFP) mice responded to Bz-ATP and ATP in a manner similar to NPCs in SVZ brain slices of the same type of animal. In short, current responses to ATP and its structural analogue were largely increased when the normal extracellular medium was changed to a low X 2+ -containing one. Concentration-response curves for the two agonists revealed a high potency of Bz-ATP in comparison to that of its mother compound. Excised patches still reacted to Bz-ATP confirming that the agonist effect has arisen at the cell under investigation rather than on neighbouring cells releasing an unknown signalling molecule. An inhibitor cocktail blocking AMPA, NMDA, and GABA A receptors as well as voltagesensitive sodium channels (CNQX, AP-5, gabazine, tetrodotoxin) also failed to interfere with the effect of Bz-ATP. In conclusion, NPCs localized in both neurogenic niches of the adult brain (SVZ, DG) are endowed with P2X7Rs. We suggest that the apoptotic/necrotic P2X7Rs at these cells may be of particular relevance during pathological conditions which lead to increased ATP release and thus could counterbalance the ensuing excessive cell proliferation. In the developing and mature central nervous system, NG2 expressing cells comprise a population of cycling oligodendrocyte progenitor cells (OPCs) that differentiate into mature, myelinating oligodendrocytes (OLGs). OPCs are characterized by high motility and respond to injury by migrating into the lesioned area to support remyelination. Oligodendrocytes express distinct voltage-gated ion channels depending on their maturation. OPCs express different purinergic receptors, including A 2A adenosine receptors and the P2Y-like GPR17 receptor. While the former is expressed during all stages of OPC maturation, the latter is poorly expressed by undifferentiated, bipolar, NG2+ OPCs and presents a peak of expression in post-mitotic, O4+ preoligodendrocytes, whereas it is absent in mature, myelinating oligodendrocytes. We recently demonstrated that, in cultured primary rat OPCs, the purinergic G i -protein coupled receptor GPR17 receptor stimulation by its agonist UDP-glucose (1-100 μM) enhances delayed rectifier K + currents (I K ). This effect is concentration-dependent and is blocked by the GPR17 antagonists MRS2179 and cangrelor, and is sensitive to the I K blocker tetraethylammonium, which also inhibits oligodendrocyte maturation. We propose that stimulation of I K currents is responsible for GPR17-induced oligodendrocyte differentiation. Moreover, we demonstrated, for the first time, that GPR17 activation stimulates OPC migration, suggesting an important role for this receptor after brain injury. On the other hand, we found that the G s -coupled adenosine A 2A receptor exerts opposite effects on K + current modulation and on differentiation in OPC cultures. In particular, we observed that the selective A 2A agonist, CGS21680 (1-100 nM), inhibits I K currents in a concentrationdependent manner and that the effect is blocked in the presence of 100 nM SCH58261, a selective A 2A antagonist. Since it is known that the block of I K currents decreases OPC proliferation and differentiation, our further aim was to investigate whether A 2A receptors modulate these processes. CGS21680, applied at 100 nM in the culture medium of oligodendrocyte cultures, inhibits OPC differentiation (an effect prevented by SCH58261) without affecting cell proliferation. We demonstrated that cultured OPCs express functional A 2A and GPR17 receptors whose activation exerts opposite effects on I K currents and on in vitro OPC differentiation. Results support that both purinergic receptors influence OPC differentiation by modulating I K currents. Data are of interest in perspective of new therapeutic strategies aimed at potentiating the post-traumatic response of OPCs under demyelinating conditions. cochlea, i.e. the developmentally regulated and cell-type specific depolarizing effects on auditory brainstem neurons of Mongolian gerbil [Milenkovic et al. 2009; Dietz et al. 2012] . Endogenous release of ATP enhances glutamate-driven firing of spherical bushy cells (SBCs) in the cochlear nucleus and principal neurons in the medial nucleus of the trapezoid body. ATP increases spontaneous and also acoustically evoked activity in vivo, but these effects diminish with maturity. Moreover, ATP not only augmented glutamate driven firing, but also evoked APs in the absence of glutamatergic transmission. In vivo extracellular recordings also revealed that endogenously released ATP in the cochlear nucleus contributes to neuronal firing activity by facilitating AP generation and prolonging AP duration. Activation of P2XRs can evoke suprathreshold membrane depolarization and generate APs by a mechanism engaging activation of the protein kinase C through an increase of cytosolic calcium concentration. The pharmacological profile is consistent with activation of heterometic P2X2/3 receptor channels, as concluded from in vivo extracellular recordings in combination with iontophoretic drug applications, and whole cell recordings in acute slices. Furthermore, analogous response properties were recorded in HEK293 cells expressing heteromeric P2X2/3R, but not homomeric P2X2R nor P2X3R. In summary, we conclude that purinergic modulation of action potential firing and resulting Ca 2+ signaling in developing auditory brainstem is conveyed by the heteromeric P2X2/3R. By providing a pathway for Ca 2+ influx and attuning neuronal activity pattern during the critical, early postnatal period of auditory circuit development, P2X2/3R might be specifically appointed to establishment of a tonotopic gradient by controlling processes such as morphogenesis, synaptogenesis or refinement of synaptic contacts. Alzheimer's disease (AD) is characterized by extracellular amyloid deposits and intraneuronal neurofibrillary tangles, made of aggregated hyper-and abnormally phosphorylated Tau proteins. The latter, referred to as "Tau pathology", contribute to synaptic impairments leading to memory deficits in AD patients. Previous epidemiological studies revealed that habitual caffeine consumption reduces the risk to develop AD. Experimental studies suggested that chronic caffeine treatment mitigates spatial memory impairments and Aβ in APP transgenic mice. Further, caffeine was also shown to reduce Aβ neurotoxicity, through A 2A -receptor blockade. However, effects of caffeine and A 2A receptor blockade towards Tau pathology remains unknown so far. The present study was aimed at evaluating the impact of chronic caffeine intake and A 2A receptors deletion on memory deficits and neuro-inflammatory processes in a transgenic mouse model (THY-Tau22) exhibiting progressive hippocampal Tau pathology. Caffeine (0.3 g/L) was chronically administered through drinking water to Tau mice and littermate controls from 2 to 12 months of age. At completion of the treatment, caffeine was readily detected in the brain and plasma of treated animals. Results showed that caffeine treatment improved spatial memory in THY-Tau22 mice. That was associated with reduced Tau phosphorylation and proteolysis. Further, caffeine treatment significantly reduced hippocampal neuro-inflammation as shown by the reduction of several pro-inflammatory markers previously found overexpressed in THY-Tau22 mice. Effects of caffeine were partly mimicked by A 2A receptor deletion and pharmacological blockade by the A 2A antagonist prodrug MSX-3. A 2A receptor blockade prevented Tau-dependent spatial memory alterations, an effect associated with a normalization of hippocampal long-term depression and Glutamate/GABA ratio as seen using microdialysis technique. Further, A 2A receptor blockade led to a significant reduction of hippocampal Tau phosphorylation but also reduced hippocampal neuro-inflammation. Altogether, the present data are the first reporting that caffeine intake and A 2A receptor deletion exert beneficial effect in a Tau transgenic mouse model of AD. These data support the therapeutic potential of both caffeine and A 2A receptor antagonists in AD. Funding: ANR (Adontage, Adoratau), France Alzheimer, LECMA, LabEx DISTALZ, FUI Medialz; Alzheimer Forschung Initiative e.V., Germany A 1 and A 3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in hypoxic murine astrocytes Stefania Gessi, Stefania Merighi, Angela Stefanelli, Debora Fazzi, Katia Varani, Pier Andrea Borea Dept of Medical Science, Pharmacology Section, University of Ferrara, Ferrara, Italy Adenosine (Ado) exerts neuroprotective and anti-inflammatory functions by acting through four receptor subtypes A 1 , A 2A , A 2B and A 3 . Astrocytes are one of its target in the central nervous system. Hypoxia-inducible factor-1 (HIF-1), a master regulator of oxygen homeostasis, is induced after hypoxia, ischemia and inflammation and plays an important role in brain injury. HIF-1 is expressed by astrocytes, however the regulatory role played by ado on HIF-1α modulation induced by hypoxic and inflammatory conditions has not been investigated. Primary murine astrocytes were activated with lipopolysaccharide (LPS) with or without ado, ado receptor agonists, antagonists and receptor silencing, before exposure to hypoxia. HIF-1α accumulation and downstream genes regulation were determined. In murine astrocytes ado inhibited LPS-increased HIF-1α accumulation under hypoxia, through activation of A 1 and A 3 ado receptors. In cells incubated with the blocker of p44/42 MAPK, LPS-induced HIF-1α accumulation and ado-mediated inhibition were significantly decreased, suggesting the involvement of p44/42 MAPK in both these effects. A series of angiogenesis and metabolism related genes were modulated by hypoxia in an HIF-1 dependent way, but not additionally increased by LPS and not modified by ado. Instead, genes involved in inflammation, like inducible nitric-oxide synthase (iNOS) and A 2B ado receptors, were strongly stimulated by LPS in concert with hypoxia and were inhibited by ado, through A 1 and A 3 receptor subtypes.
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In conclusion Ado A 1 and A 3 receptors reduce the LPS-mediated HIF-1α accumulation in murine astrocytes, resulting in a downregulation of genes involved in inflammation like iNOS and A 2B ado receptors.
Adenosine modulates neuronal network activity in the mouse olfactory bulb Christian Lohr, Natalie Rotermund, Kristina Schulz, Daniela Hirnet Division of Neurophysiology, University of Hamburg, Germany Neuromodulation by ATP, ADP and adenosine is unique with regard to its complexity and specificity, achieved by tissue-specific combinations of transmitters with a variety of receptor subtypes, second messenger systems, transporters and enzymes. ATP and its metabolites, in particular adenosine, are ubiquitous co-transmitters and neuromodulators, participating in synaptic transmission as well as in neuron-glia interactions. Proteins associated with the purinergic signalling system are highly expressed in the olfactory bulb of rodents, suggesting purinergic modulation of olfactory information processing. In the present study, we focus on the effect of adenosine on the neuronal network activity in the olfactory bulb. We monitored the activity of olfactory bulb neurons by recording postsynaptic whole-cell currents of mitral cells, the output neurons of the olfactory bulb. Bath application of adenosine reversibly reduced the frequency of spontaneous synaptic inputs in mitral cells. DPCPX, a specific antagonist of the A1 receptor subtype, blocked the effect of adenosine. We used paired-pulse stimulation of receptor axons and imaging of vesicle fusion in OMP-synapto-pHluorin mice to test the effect of adenosine on synapses between receptor axons and mitral cells. Adenosine neither changed the amplitude of the EPSC response nor the paired-pulse ratio as compared to control stimulations. Similarly, vesicle fusion in presynaptic structures of ORNs did not change in the presence of adenosine. In contrast, analyses of mitral-to-granule cell synaptic connections suggest an influence of adenosine on the performance of this dendrodendritic synapse. Current clamp recordings show a direct hyperpolarising effect of adenosine and a reduction of the excitability of olfactory bulb mitral cells. These effects seem to be mediated by the activation of a potassium conductance by A1 receptors. Morphological and physiological evidence indicate that A1 receptors are located on mitral/tufted cells and affect other olfactory bulb neurons indirectly by decreasing the excitability of these major output neurons. Financial support for this project is permitted by the DFG (Lo779/6). In the present study we addressed such issues by different experimental approaches in R6/2 mice (the most widely used transgenic model of HD) and in cellular HD models. Electrophysiological recordings of extracellular field potentials in corticostriatal slices demonstrated that the A 1 R agonist ciclopentyladenosine (CPA, 300 nM for 20′) was significantly more effective in reducing synaptic transmission in symptomatic (11-13 weeks of age) R6/2 than in age-matched WT mice (mean FP amplitude: 27.03±4.67 % and 51.22±6.30 % of basal in R6/2 and WT, respectively; P <0.05). Both paired-pulse stimulation protocol and K + -evoked glutamate efflux from synaptosomes demonstrated that the increased CPA effect in R6/2 mice depended on a higher inhibition of pres-synaptic glutamate release. All the above reported CPA effects were fully prevented by the A 1 R antagonist DPCPX. Binding studies revealed that the density of A1Rs was significantly reduced in the cortex (Bmax 347±3 vs 467±14 fmol/mg protein) and the striatum (Bmax 250±6 vs 373±2 fmol/mg protein) of R6/2 vs. WT mice, while receptor affinity was not affected. To try to understand the mechanisms of the increased A 1 R-mediated effects, we evaluated (western blot) the expression of adenosine deaminase (ADA), that (besides regulating adenosine levels) can modulate the functions of A 1 Rs. ADA levels were not significantly changed in membranes, while they were significantly reduced in the cytosol of R6/2 mice. The different functional activity of A 1 Rs in HD mice was associated also to a different intracellular signaling pathway. In fact, while the PKA pathway was involved in both genotypes, p38 MAPK inhibitor SB203580 partially prevented synaptic CPA effect in R6/2 mice (51.90±8.76 % of basal; P <0.05 vs. CPA alone) but not in WT; moreover, CPA differently modulated the phosphorylation status of p38 in the two genotypes. Finally, we analysed the ability of CPA to modulate motor activity in R6/2 and WT mice and, at least at presymptomatic stage (6 weeks), we found no changes. In vitro studies confirmed a different behavior of A1Rs in cellular models of HD. In conclusion, our results demonstrate that in presence of the HD mutation A 1 Rs undergo profound changes in terms of expression, pharmacology and functional activity. These changes have to be taken in due account when considering A1Rs as a potential therapeutic target in HD.
Potential therapeutic targets for
Adora signaling in hypoxic neurons
Bettina Thauerer, Gabriele Baier-Bitterlich Medical University of Innsbruck, CCB-Biocenter, Div. of Neurobiochemistry, Innrain 80-82, A-6020 Innsbruck, Austria
Multiple signaling pathways regulate the critical balance between cell death and survival in hypoxia-ischemia. A convergent pathway for the regulation of multiple modalities involved in O 2 sensing is the mitogen activated protein kinase (p42/44 MAPK or ERK1/2 extracellular signal-regulated kinases) pathway terminating in a variety of transcription factors, for example, hypoxia-inducible factor 1 alpha (HIF-1alpha). An alternative pathway involves the activation of the protein kinase C-related kinase (PRK1, PKN1) (for a review see: Thauerer B., Zur Nedden S. and Baier-Bitterlich G. (2012) Purine nucleosides: endogenous neuroprotectants in hypoxic brain. Journal of Neurochemistry 121, 329-42). We developed an in vitro and an ex vivo neuronal cell model to study hypoxic stress and endogenous neuroprotective pathways. In hypoxic PC12 cells, viability is predominantly rescued by adenosine and hypoxia-induced membrane responses of PC12 cells are likely to be mediated via activation of the ADORA2A/MAPK/HIF-1alpha module. Guanosine is more supportive of neurite outgrowth and was shown to involve PKN1. In primary cerebellar granule neurons ADORA1 is the predominant signaling module. In this presentation, the coherence of purine nucleoside-related pathways and MAPK-and PKN activation in the endogenous neuroprotective regulation of neuroplasticity under hypoxic stress will be discussed. Supported by the Austrian Science Fund (FWF) T421.B18, P19578-B05 and P26002-B24
Purinergic receptors and cortical network activity
Zoltan Gerevich
Institute of Neurophysiology, Charité -Universitätsmedizin Berlin, Berlin, Germany Rhythmic network activity is observed in several cortical networks and is a critical component of neural signal processing. In particular, gamma frequency oscillations (30-80 Hz) are involved in higher cognitive functions such as sensory processing, attention, learning and memory. Alterations in gamma oscillations are associated with psychiatric diseases such as schizophrenia. On the other hand, hypersynchronous neuronal firing is a well-known trait of epileptic seizures. Since ATP is released from cells during neuronal activity, we investigated whether ATP is able to modulate two forms of network activities: gamma oscillations and epileptiform discharges. Hippocampal gamma oscillations were inhibited by endogenously released ATP via the stimulation of adenosine A1, P2X2 and/or P2X4 receptors whereas P2Y1 receptors had stimulatory effects. Epileptiform discharges in the entorhinal cortex were inhibited by activation of adenosine A1 receptors while P2X7 receptors had pro-epileptic effects. No other P2 receptors affected the epileptiform activity. Thus, endogenously released ATP and its degradation products activate various purinergic receptors and control physiological and pathophysiological neuronal network activity. The exact effect of ATP depends on the actual activity of ectonucleotidases and the expression level of the purinergic receptors which can vary between different disease states. Our data also suggest that ligands at P2Y1, P2X2 and/or P2X4 receptors may be novel targets for antipsychotics and P2X7 receptor antagonists have antiepileptic effects. Purine nucleoside phosphorylase (PNP) is an ubiquitous enzyme that catalyses the reversible phosphorolysis of purine nucleosides into their corresponding nucleobases, playing a key role in the purine salvage pathway by allowing the cell to produce nucleotide monophosphates. Changes in PNP expression/activity has been associated with a T-cell lymphopenia-mediated immunodeficiency, neurological dysfunctions, inflammation and cancer progression. Glial cells, that express high levels of PNP, largely contribute to the onset and progression of these syndromes, and in this context, it is to be emphasized that glial-derived adenine-and non-adenine based nucleosides, whose levels are regulated by PNP activity, exert remarkable neuroprotective/neurotrophic effects. It is well known that most of the enzymes involved in purine metabolism are present, as ecto-enzymes, on the external surface of plasma membranes, but so far no membrane localization of PNP has been reported. In order to better elucidate the pathophysiological role of PNP, in this study we evaluated the expression and the activity of PNP both in the cytosol and in purified membrane preparations derived from rat cultured neurons, astrocytes, microglia and C6 glioma cells. Either western blot or confocal and electron microscope analysis, indicated the presence of the enzyme in purified membrane preparations. To evaluate the enzymatic activity, instead of the traditional spectrophotometric method, we have developed a new, simple and sensitive HPLC method with fluorescence or on-line radiochemical detection. By using guanosine as substrate, a specific activity was detected both in the cytosol and in the membrane preparations. The resulting curves showed a very good fit with Michaelis-Menten equation and the obtained Km values were very similar. Since a PNP activity has been found in some extracellular milieu such as rat plasma (Giuliani et al., J Biol. Regul. Homeost. Agents 26:51-65. 2012) and gingival crevicular fluid (Batista EL. Et al. J Periodoantal Res. 45(5):664-71. 2010) but the source of this enzyme is still widely unknown, we wondered whether our different cerebral cell cultures were able to release PNP in the medium. Interestingly, we found that the above mentioned cultured cells, especially glial cells, were able to release PNP which began to be detectable after 2 h. The enzymatic parameters found for this soluble isoform were very similar to those measured in the cytosol and purified membrane preparations. Also PNP present in the plasma showed very similar functional characteristics. The PNP released in the culture medium was modulated in a time-and dose-dependent manner by different purine receptor agonists, such as BzATP, NF546, or GUO. Moreover, cell exposure for 30 min to a combined glucose and oxygen deprivation reduced the expression of PNP found in the extracellular milieu while cell exposure to TGF-β, to mimic an epithelial-to-mesenchimal transition, significantly increase extracellular PNP levels.
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These data suggest that plasma PNP could reasonably represent the mirror of the peri-cellular and intra-cellular PNP and could be proposed as a potential bio-marker for the diagnosis and progression of the above mentioned syndromes.
Molecular substrates of P2X7-like background currents
Wolfgang Nörenberg, Helga Sobottka, Tanja Plötz, Michael Schaefer Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany
The P2X7 receptor displays unique properties amongst the ion channel-coupled purinergic P2X receptors. It requires high ATP concentrations to become activated, confers non-inactivating cation currents that further increase over time or during repetitive stimulation, and undergoes agonist-and timedependent pore dilation, allowing organic cations to permeate into the cell. When investigating the P2X7-mediated conductance, we consistently observed background currents that were present in non-transfected parental HEK293 cells or in other cell models, including the C6 rat glioblastoma cell line that has been reported to functionally express P2X7. Biophysical hallmarks that are reminiscent of a P2X7-mediated conductance include the noninactivating current kinetic that increased during repetitive exposure to 1-10 mM ATP, a linear I/V relationship, and a reversal potential close to 0 mV. Astonishingly, however, these background currents were not associated with discernible increases in the intracellular Ca 2+ concentration, or with membrane permeation of the cationic dye Yo-Pro-1. In addition, potent and selective P2X7 receptor antagonists such as AZ10606120 or A438079 failed to suppress this conductance at concentrations that are reported to fully block P2X7. These findings prompted us to consider other cation channel entities as the molecular correlate of this background conductance. By applying Mg 2+ -free pipette solutions, we ruled out indirect effects via P2Y receptormediated signaling pathways. Instead, experimental evidence indicates that background currents are caused by ion channel entities that are not part of the purinergic receptor families, thereby extending the class of molecular targets that may be regulated by high extracellular concentrations of ATP.
Cask is a novel interactor of P2X3 in sensory neurons
Elsa Fabbretti University of Nova Gorica, Center for Biomedical Sciences and Engineering, Vipava, Slovenia.
Increasing evidence indicates the importance of extracellular ATP in the modulation of neuronal function. In particular, fine control of ATP release and the selective and discrete ATP receptor operation are crucial elements of the crosstalk between neuronal and non-neuronal cells in the peripheral and central nervous systems. In peripheral neurons, ATP signaling gives an important contribution to neuronal sensitisation, especially that involved in neuropathic pain. Among other subtypes, P2X3 receptors expressed on sensory neurons are sensitive even to nanomolar concentrations of extracellular ATP, and are important transducers of pain stimuli. P2X3 receptor function is highly sensitive to soluble factors like neuropeptides and neurotrophins, and is controlled by transduction mechanisms, protein-protein interactions and discrete membrane compartmentalization. More recent findings have demonstrated that P2X3 receptors interact with the synaptic scaffold protein CASK in a state dependent fashion, indicating that CASK plays a crucial role in the modulation of P2X3 receptor stability and efficiency. Activation of P2X3 receptors within CASK/P2X3 complex has important consequences for neuronal plasticity and possibly for the release of neuromodulators and neurotransmitters. Better understanding of the interactome machinery of P2X3 receptors and their integration with other receptors and channels on neuronal surface membranes, is proposed to be essential to unveil the process of neuronal sensitisation and related, abnormal pain signalling.
Initial characterization of a P2X7-EGFP BAC transgenic mouse model
Annette Nicke Max Planck Institute for Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany Studies on P2X7-deficient mice established an important role of this receptor in inflammation and neuropathic pain. However, investigation of this receptor in native tissue preparations has been challenging. Thus, despite their importance as drug targets, their precise localization, physiological functions, and regulation under pathophysiological conditions remain poorly understood. In particular, the location and function of P2X7 receptors in the central nervous system and their interactions with other proteins are largely unknown. To provide models that allow a more specific investigation of this receptor, we have generated bacterial artificial chromosome (BAC) transgenic mouse lines in which a Strep-His-GFP-tagged P2X7 receptor is over-expressed under the control of P2X7 regulatory elements. Preliminary analysis shows that the GFP-tagged receptor can be directly visualized by confocal and fluorescence microscopy and is efficiently transported to the plasma membrane. Thus the generated mouse models are suitable to determine the cellular and subcellular localization of P2X7 receptors in the nervous system. Initial biochemical studies demonstrate that the transgenic P2X7 receptors can be efficiently purified from different native tissues via their His-or GFPTags and are assembled in complex with endogenous P2X7 subunits. In conclusion, we provide a novel mouse model that should be able to answer many of the unresolved questions in the P2X7 receptor field. Astrocytes represent a major part of glial cells in CNS and constitute important structural component of the blood brain barrier (BBB). We investigated the biological response evoked in astrocytes and CD4+ T cells upon their reciprocal interaction, shedding light on the role of nucleotides in the intercellular signalling between these two cell types. T cell co-stimulation through purinergic P2X receptors, upon TCR triggering, sustains MAPK pathway activation, whereas blockade of purinergic co-stimulation results in T cell anergy. Conversely, P2X7 stimulation in the absence of TCR activation determines T cell apoptosis. Thus, extracellular ATP and purinergic signaling play a crucial role in conditioning T cell fate. We determined extracellular ATP levels by the luciferin/luciferase assay in the supernatant of astrocyte-T cell co-cultures. Our data revealed a reduced concentration of extracellular ATP in the presence of T cells, suggesting that T cells may partially inhibit ATP release and/or hydrolyze ATP released from astrocytes. In line with this evidence, we also observed a reduction of spontaneous calcium oscillations in astrocytes when co-cultured with activated T cells. Moreover, we analyzed by flow cytometry the expression of the ectonucleotidases CD39 and CD73, which hydrolyze ATP to ADP-AMP and AMP to adenosine, respectively. A strong induction of both ectonucleotidases was detected in T cells after 48 and 96 h of co-culture and the effect was more pronounced in T cells adhering to astrocytes. Since CD73 expression is associated with BBB permeability and is involved in T cells entry into the brain during EAE, the mouse model of multiple sclerosis, our data suggest that the interaction between astrocyte and T cell could play an important role both in physiological and pathological conditions.
Extracellular nucleotides in astrocyte/T cell interaction
SYMPOSIUM 7 PURINES AND CANCER
The purinergic P2X7 receptor mediates the secretion of ATP and enhances sensitivity to chemotherapeutic drugs in lymphoma cells Vera Labitzky, Janne Becher, Soruh Nader, Bjarne Johnsen, Welbeck Danquah, Friedrich Knoch-Nolte, Friedrich Haag Institute of Immunology, University Medical Center Hamburg-Eppendorf Extracellular ATP (eATP) concentrations are elevated in many tumors. By acting on purinergic P2X or P2Y receptors, eATP and its breakdown products exert multiple effects on tumors, including the transmission of survival signals and regulation of the anti-tumor immune response. Among other receptors, eATP acts on the P2X7 receptor, which is expressed by cells of the immune system and also by many tumors. Accumulation of eATP formerly was thought to result mainly from necrotic tissue damage, but awareness is increasing that many cell types actively secrete ATP in a regulated fashion. While investigating the effects of eATP on Yac mouse T lymphoma cells, we found that activation of the P2X7 receptor caused a decrease in their intracellular ATP content accompanied by a rise in the extracellular ATP concentration. In addition, Yac cells responded in multiple ways to P2X7 activation, including the shedding of cell surface CD62L and the externalisation of phosphatidylserine to the outer leaflet of the cell membrane -a characteristic of cells entering a pre-apoptotic stage. We also detected P2X7-dependant pore formation by monitoring the uptake of fluorescent dyes. We speculated that ATP might be released through the same pores that permit dye entry. However, pharmacological evidence indicates that ATP release and dye uptake occur by separate mechanisms. Stimulation by eATP strongly induced phosphorylation of the MAP kinases Erk1/2 in Yac cells, a pathway known to transmit anti-apoptotic survival signals to the cell. However, co-treatment of Yac cells with ATP synergistically enhanced the cytotoxic effects of the chemotherapeutic drug doxorubicine (Doxo). Further analysis revealed that incubation of cells for 1 h with ATP and Doxo, followed by washing and incubation in normal growth medium, was sufficient to induce the synergistic cytotoxic effect.
In conclusion, our studies show that Yac lymphoma cells actively secrete substantial amounts of ATP into the extracellular environment in response to extracellular signals, including P2X7 activation. Under "steady-state" conditions, this released ATP may amplify P2X7 signalling or act on other purinoreceptors to modulate tumor growth and the anti-tumor immune response. In the context of chemotherapy, P2X7 signalling may amplify drug effects by increasing drug uptake and synergistically feeding in to drug-induced cell death pathways.
Insight on P2X 7 receptor role as oncogene . Nevertheless, a clear cut demonstration that P2X7 receptor can affect carcinogenesis in vivo was missing. Aim of our studies was to verify the effect of P2X7 expression and blockade in animal models of cancer. Tumor tested included colon cancer, melanoma and neuroblastoma modeled either in syngeneic or in xenograft systems. In all this settings P2X7 was increasing tumoral engraftment and growth rate also affecting blood vessels formation [Adinolfi et al., 2012] . Signaling cascades involved in P2X7 mediated transformation included the HIF-1 alpha-VEGF and PI3Kinase-GSK3 axes. Of interest for the therapy of cancers that are still lacking a cure, such as advanced stages neuroblastoma and melanoma, was the power of different P2X7 inhibitors to in vivo reduce cancer growth. In summary, our data demonstrate an oncogenic role for P2X7 receptor and suggest it as easily approachable therapeutic target as its antagonists are in clinical trials for other diseases and will be soon available at patient's bed. This work was partially supported by My first AIRC Grant 11630 to EA Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor Dagmar Schumacher, Boris Strilic, Kishor Kumar Sivaraj, Nina Wettschureck, Stefan Offermanns Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany Tumor cells can activate platelets which in turn facilitate tumor cell survival and dissemination. The exact mechanisms by which platelets promote metastasis have remained unclear. Here we show that adenine nucleotides released from tumor cell-activated platelets induce opening of the endothelial barrier to allow transendothelial migration of tumor cells and thereby promote cancer cell extravasation. We identified the endothelial P2Y 2 receptor, which is activated by ATP, as the primary mediator of this effect. Mice deficient in P2Y 2 or lacking ATP-secretion from platelets show strongly reduced tumor cell metastasis. These findings demonstrate a novel mechanism by which platelets promote cancer cell metastasis and suggest the P2Y 2 receptor and its endothelial downstream signaling mechanisms as a target for anti-metastatic therapies.
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The effect of P2X7 receptor polymorphisms on osteoblast cells The P2X7 receptor (P2X7R) gene is highly polymorphic with at least six non-synonymous single-nucleotide polymorphisms (SNPs) being previously described as having either loss-of-function (LOF) or gain-of-function (GOF) effects. We have previously demonstrated expression of functional P2X7R on both osteoblasts and osteoclasts and found an association of LOF P2RX7 polymorphisms and LS-BMD. The exact mechanism behind this observed association is currently unknown. We provide evidence here that it is the effects of P2XR7 SNPs on osteoblast cells that may be driving the observed association with lower BMD in individuals with P2XR7 SNPs.
To determine the effect of P2XR7 SNPs on osteoblast cell function, Te85 cells were transfected with P2XR7 wild type (WT) or SNPs cDNA. P2X7R activation, intracellular calcium levels, cell proliferation, alkaline phosphatase (ALP) activity and in-vitro mineralisation were measured. Transfected WT or P2XR7 SNPs did not function in Te85 cells unless co-transfected with a naturally occurring truncated isoform, splice variant B (P2X7B). Upon ATP stimulation, pore formation was observed in the WT and GOF SNP, 155Y; but not in any of the three LOF SNPs; 496A, 568 N, or 307Q. Increased intracellular calcium levels were found in all co-transfected Te85 cells, compared to the naïve or single P2X7B transfected cells. As expected, cell proliferation increased in Te85 cells transfected with the trophic P2X7B isoform, but co-transfection of WT or P2XR7 SNPs reduced cell proliferation. Transfection of P2X7B alone significantly decreased ALP activity by 23 % compared to naïve cells, whilst co-transfection of P2X7B and WT significantly increased ALP activity by 36 %. Co-transfection with the LOF 496A and 568 N P2XR7 SNPs gave significant decreases in ALP of 15 % and 13 % respectively. In-vitro mineralisation was also significantly increased with co-transfection of P2X7B and WT or 307Q SNP compared to naïve cells, but this increased mineralisation was not detected with other P2XR7 SNPs.
The results of this study demonstrate that the P2X7B isoform is necessary for P2X7R-mediated osteogenesis in Te85 osteoblasts cells and that P2XR7 SNPs significantly alter osteoblast cell function which may account for the reduced BMD previously observed in women with P2X7R polymorphisms. The results of this study extend our knowledge into the role of the P2X7R in maintaining bone homeostasis, and may help identify people at risk of developing osteoporosis.
The role of adenosine receptors in adipocytes 2012; 287: 15718-15727] . In the present study we developed a new indole-derivative (LUC 1242) as the first positive allosteric modulators (PAM) of the human A 2B AR and we investigated the potential activity of this compound as osteogenic agent. LUC 1242, both in A 2B AR-transfected cells and MSC, behaved as selective PAM of A 2B AR subtype. This modulator was able to increase the effects of A 2B AR orthosteric agonists on the expression of osteogenic markers (Runx2, Osterix, alkaline phosphatase and osteocalcin) and on osteoblast mineralization. Furthermore the survival of the differentiated cell was enhanced by the A 2B orthosteric agonist, and much more in the presence of PAM. Overall these data suggest that the development of more drugs targeting allosteric sites of A 2B ARs may represent an innovative unrecognized target for local regulation of osteoblast cell proliferation and differentiation, prompting for new strategies to control disorders where bone destruction exceeds bone formation (e.g., osteoporosis, rheumatoid arthritis, multiple myeloma, fracture mal-union). It is noteworthy that, allosteric modulation of membrane receptors is now considered to be an important indirect mechanism for the control of receptor function with several advantages: an allosteric modulator in contrast of its native, orthosteric activator, has a greater site and event selectivity and, acting only through the enhancement of endogenous agonist responses, is fewer prone to side effects. CD39 and CD73 catalyze the hydrolysis of extracellular nucleotides to adenosine to regulate inflammatory reactions and tissue repair. We have shown that hematopoietic stem cells (HSC) are mobilized from the bone marrow after liver injury in mice and humans and modulate vascular inflammation and liver regeneration in an ectonucleotidase-dependent manner. Our recent work indicates that activated HSC additionally shed plasma microparticles (MP) after surgical and pharmacological liver injury. HSC derived MP express CD39 and CD73 with their expression profiles being associated with the severity of liver injury in both mice and patients. Beside a potential role of ectonucleotidase-bearing MP as novel biomarkers in liver disease, these transport vesicles contain stem cell-specific microRNA (miR) and might act as intercellular carriers. Advanced flow cytometry techniques allow us to sort plasma MP according to their surface profiles for further analysis. Our preliminary data suggest that miR levels in plasma MP are modulated by CD39 and CD73 after liver injury and are regulated by extracellular nucleotides in a P2X7-dependent manner. Experiments investigating the relevance of HSC derived plasma MP and miR levels for intercellular communications between bone marrow compartments and primary liver cells such as sinusoidal endothelial cells and hepatocytes are on the way.
Ectonucleotidase bearing plasma microparticles in liver disease
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UTP and ATP induce transient target phosphorylation in cardiac myocytes Extracellular UTP and ATP can be released from the mammalian heart during pathological conditions such as ischemia, hypoxia or reperfusion. In humans, UTP and ATP levels are increased during myocardial infarction. UTP can act via P2Y-purinoceptors. In electrically driven (1 Hz) mouse atrial and ventricular preparations and atrial preparations from patients undergoing cardiac bypass surgery, we noted a time and concentration-dependent positive inotropic effect of UTP (cumulatively applied from 10 to 100 μM). To investigate the involved signal transduction pathway, we studied the effects of UTP and, for comparison, ATP on MAPK phosphorylation in isolated adult mice cardiac myocytes, in neonatal rat cardiac myocytes and in human cardiac atrial tissue using phosphorylation-specific antibodies. UTP (and ATP) time and concentration-dependently increased phosphorylation of ERK1/2 and p38 MAPK with a maximum effect at 5 to 10 min after application of UTP in cardiac myocytes (n =3 preparations each). In summary, we noted an UTPinduced phosphorylation of ERK1/2 and p38 MAPK in isolated rat and mouse cardiac myocytes. The UTP-induced phosphorylations were blocked by PPADS but not by DPCPX or reactive blue. In preliminary experiments, we noted increased ERK1/2 and p38 MAPK-phosphorylation in human atrial tissue due to 100 μM ATP or UTP. In summary, not only in animal cardiac preparations but also in human tissue, ATP and UTP induced increased but transient phosphorylation of regulatory proteins with marginally different time maxima, suggesting a comparable signal transduction cascade. Interestingly, the inotropic effects lasted much longer than the phosphorylations reported here. This indicates that only the initial phase of force generation can at present be explained, whereas the mechanism(s) for the sustained positive inotropic effect need further study and are suggested to involve downstream phosphorylations.
Molecular actions of the platelet P2Y 12 -receptor antagonists cangrelor, prasugrel and ticagrelor Ivar von Kügelgen, Kristina Hoffmann Pharma Center Bonn, Department of Pharmacology and Toxicology, University of Bonn, Germany
The P2Y 12 -receptor is the target of potent platelet aggregation inhibitors used for the reduction of thrombotic cardiovascular events. Prasugrel and ticagrelor have recently been approved for use in pharmacotherapy and cangrelor is under investigation in clinical trials. We analysed the molecular modes of action of cangrelor, of the active metabolites of prasugrel (R-138727) and of ticagrelor on the recombinant human P2Y 12 -receptor or mutant constructs stably expressed in 1321N1 astrocytoma cells or Chinese Hamster Ovary (CHO) cells. Receptor function was assessed by determining the effects of the agonists ADP and 2-methylthio-ADP on intracellular cAMP levels or gene expression in reporter gene assays. The nucleotide analogue cangrelor shifted the concentration-response curve of 2-methylthio-ADP to the right with an apparent pK B value of 9.2 when tested in cells expressing the wild type receptor. The antagonism was surmountable. In contrast, in cells expressing the Ser101Ala mutant of the P2Y 12 -receptor cangrelor displayed a non-surmountable mode of antagonism in agreement with an interaction of cangrelor with the residue Ser101 (transmembrane region 3) or an adjacent residue. The active metabolites of prasugrel R-138727 (1 and 3 μM) blocked P2Y 12 -receptor function in an irreversible manner. The inhibitory effect of R-138727 was maintained in cells expressing the Cys17Ala/Cys270Ala mutant of the P2Y 12 -receptor. In contrast, there was no antagonistic action of R-138727 in cells expressing the Cys97Ala or Cys175Ala mutant constructs indicating an interaction of R-138727 with the disulphide bridge formed by Cys97 and Cys175. In cells expressing wild type P2Y 12 -receptors, ticagrelor (3 to 10 nM) shifted the concentration-response curves of 2-methylthio-ADP in a concentration-dependent manner to the right in agreement with a competitive antagonism. Schild plot analysis revealed a pA 2 value of 8.7 with a slope not different from unity. There was also a surmountable antagonism of the effect of ADP by ticagrelor with a pK B value of 8.8. These data are again in agreement with a competitive mode of antagonism of ticagrelor at the human P2Y 12 -receptor. The antagonistic potency of ticagrelor was maintained in cells expressing the Ser101Ala, Lys173Ala/Lys174Ala, Cys248Ala, Arg256Ala and Lys280Ala mutant constructs of the P2Y 12 -receptor. In contrast, there were no or only minor shifts of the concentration-response curves of 2-methylthio-ADP and ADP in cells expressing the Cys194Ala mutant of the receptor. This indicates an interaction of ticagrelor with Cys194 (transmembrane region 5) or a nearby residue. In summary, cangrelor and ticagrelor are competitive antagonists at the human P2Y 12 -receptor with apparent affinity values of 0.6 nM and 2 nM, respectively. Cangrelor is likely to interact with a residue in the extracellular portion of transmembrane region 3 and ticagrelor with a residue in transmembrane region 5. The active metabolites of prasugrel R-138727 interact at low micromolar concentrations and in an irreversible manner with Cys97 and Cys175 of the human P2Y 12 -receptor.
P2 receptor signalling in acute lung injury
Marco Idzko COPD & Asthma Researchgroup (CARG); University of Freiburg, Germany
Increasing evidences point out to an important role of extracellular nucleotides (such as ATP, UTP) and their receptors (P2X and P2Y-receptors) in the modulation of immune responses in inflammatory airway diseases. We could recently show that inhibition of ATP/P2R-pathway can reduce all cardinal features of ongoing chronic inflammatory lung disease such as asthma and COPD. Acute respiratory distress syndrome (ARDS), a lung injury state with a high mortality rate, occurs in the setting of acute severe illness complicated by systemic inflammation. Intratracheal administration of LPS to rodents is an well accepted experimental model for ARDS, as it causes all the pathological condition of ARDS, such as profound neutrophil lung recruitment, vascular leakage/lung oedema and subsequently systemic inflammation. Recently a important role of the ATP-metabolite Adenosine (via A2B-receptor) in controlling neutrophil recruitment and plasma leakage in the LPS-induced ARDS has been demonstrated. However little was known about the role of P2R-signalling in ARDS. Here we report that following pulmonary LPS-challenge endogenous ATP is released to the airways, which was accompanied with up-regulation of specific P2Y and P2XR-subtypes expression in lung tissue of these mice. These observations seem to be of pathophysiological relevance, as degrading pulmonary ATP-levels or broad-blocking of pulmonary P2R decrease all classical features of ARDS. By using BM-chimera and subtype specific P2R-knockout mice or inhibitors we could enlighten the important role of the P2X7R, P2Y2R and P2Y6R-signalling in the pathogenesis of ARDS. In summary our data implicates these P2R-subtypes as new therapeutic targets for the ARDS.
Metabolic relevance of P2Y12-like receptors
Torsten Schöneberg Molecular Biochemistry, Institute of Biochemistry, Medical Faculty, University of Leipzig The P2Y12-like receptor group comprises several structurally related GPCR with a long evolutionary history. Several members of the P2Y12-like receptor group, which includes the clopidogrel-sensitive ADP receptor P2Y12, have been deorphanized recently. They, however, display heterogeneous agonist specificity including nucleotides, their derivatives, and lipids. Besides the established function of P2Y12 in platelet activation, expression in macrophages, neuronal and glial cells as well as recent results from functional studies implicate that several members of this group may have specific functions in neurotransmission, inflammation, chemotaxis, and response to tissue injury. Although expressed in many tissues their metabolic relevance is mostly unknown. Analysis of metabolic functions in several P2Y12-like receptor-deficient mouse strains revealed previously unappreciated roles in regulating body weight, energy homoeostasis and insulin release. The talk will summarize current data on gene-deficient mouse models for P2Y12-like receptors with special focus on metabolic phenotypes. The purinergic P2X7 receptor is expressed in both the bone forming osteoblasts, in bone resorbing osteoclasts, and in the mechanosensory osteocytes. The P2X7 receptor has primarily been shown to regulate cell death and survival, and is important in cell growth and differentiation. P2X7 receptor null mice have been shown to have reduced bone mass compared to wild type mice. In contrast, P2X7 receptor null mice seem to be protected against bone loss upon estrogen withdrawal. Thus, the role of the P2X7 receptor in regulation of bone turnover is complex. The aim of the study was therefore to investigate the effect of a P2X7 receptor inhibitor on bone cell activity in vitro and bone turnover in vivo. The selective P2X7 receptor antagonist AFC-5261 was added to the culture medium of primary human osteoblasts and primary murine osteoblasts. Expression of genes related to osteoblast differentiation and bone forming activity (RUNX2, COL, ALP) was determined using quantitative polymerase chain reaction (QPCR), and in vitro bone forming activity was determined using the Alizarin Red mineralization assay. Also, osteoclast formation and bone resorbing activity was determined in vitro on dentine disks. In vivo effects on bone turnover were determined in a mouse model of estrogen deficiency, where Balb/cJ wild type mice were ovariectomized at age 16 weeks. After an additional month of bone loss, they were treated with one of three doses AFC-5261 or vehicle for 4 weeks. At sacrifice, the following parameters were determined: bone mineral density (BMD), bone strength, bone turnover markers (CTX-I and Procollagen type 1 (P1NP)), and bone structure were determined. In vitro, P2X7 receptor inhibition exerted a dose-dependent induction of genes related to bone formation and osteoblast differentiation, and subsequently an increase in the formation of mineralized matrix. In contrast, the formation of mature osteoclasts was unaffected by P2X7 antagonism. However, a clear reduction of 50 % (p <0.01) in the resorptive activity was seen. In vivo, a small, but significant dose-dependent increase in BMD of app. 5 % (p <0.001) was detected. More interestingly, bone strength at the femoral neck was increased by almost 50 % (p <0.01). Markers of bone turnover showed more than 100 % increase in the bone formation marker (P1NP), while the resorption marker was reduced by 30 % (p <0.001).
The results of this study show that P2X7 receptor inhibition stimulates the formation of mineralized bone matrix and inhibits the activity of osteoclastic bone resorption in vitro, while it acts like an anabolic and antiresorptive stimulus to bone in vivo. Thus, inhibition of the P2X7 receptor is a novel target for treatment of diseases of bone loss such as osteoporosis. The P2X7 receptor (P2X7R) is an ATP-gated nonselective Ca 2+ permeable cation channel, which for example is found coexpressed with the TMEM16A(a)/anoctamin-1 (Ano-1) anion channel in secretory epithelia. The Ano-1 channel is activated by increase in the intracellular Ca 2+ concentration. To screen for a possible physical interaction between the P2X7R and Ano-1, we coexpressed His-tagged and StrepII-tagged versions of the P2X7R and the Ano-1 in Xenopus oocytes and purified the proteins under non-denaturing conditions. Besides we investigated by using the two-microelectrode voltage-clamp technique whether the coexpressed channels are functionally coupled. Indeed, coexpression of Ano-1 with the P2X7R led to a significant and sustained augmentation of the ATP-induced current compared to the current mediated by the singly expressed P2X7R. This Ano-1-dependent current increase was diminished in Ca 2+ -free extracellular solution, by buffering the oocyte cytosol with BAPTA or by the coapplication of the anion channel blockers niflumic acid or carbenoxolone with ATP. In contrast to the sustained P2X7R-mediated activation of the Ano-1 current, increasing the intracellular Ca 2+ concentration by activating the coexpressed G-protein-coupled P2Y1 receptor (P2Y1R) or by a Ca 2+ ionophore produced only a transient increase in the Ano-1-mediated anion conductance. Biochemically we did not observe a co-purification of the Ano-1 with the P2X7R or the P2Y1R by immunoprecipitation or Strep-Tactin purification, even when weak proteinprotein interactions were stabilized by chemical cross-linking. This indicates that the P2X7R-mediated or the P2Y1R-mediated stimulation of Ano-1 is not mediated by a direct protein-protein-interaction. We conclude that P2X7R stimulation may permanently activate Ano-1, a process which may be of relevance for the time course of stimulus-secretion coupling in secretory epithelia. The P2X7 receptor (P2X7R) is known to be involved in both osteoclast formation and apoptosis, and the gene for P2X7R is highly polymorphic with >600 reported single nucleotide polymorphisms. We have previously found an association of loss-of function P2RX7 SNPs and lower LS-BMD in postmenopausal women. Whilst the exact mechanism for this association is unknown, increased bone loss in postmenopausal women is known to be via loss of oestrogen, due to the increased generation, activity and reduced apoptosis of osteoclasts. In this study we provide evidence that the P2X7R in combination with depletion of oestrogen results in further significantly increased osteoclasts formation with an enhanced resorption activity. Bone marrow (BM) or splenic precursor cells isolated from P2X7R−/− mice were cultured in osteoclastogenic and in oestrogen depleted conditions on dentine. The formation and function of osteoclasts was then measured. P2X7R−/− BM cultures had significantly reduced resorption ability in comparison to P2X7R+/+ cultures (8.59 μm 2 vs 16.20 μm 2 per osteoclast, p =0.040) but only slightly more resorbing osteoclasts. Devoid of oestrogen, cells from both P2X7R−/− and P2X7R+/+ mice had increased osteoclasts and resorption. However, the change in resorptive capacity was significantly higher in osteoclasts from P2X7R−/− compared to P2X7R+/+ mice (10 vs 4 fold, p =0.010). Compared to the splenic cells of P2X7R+/+ mice, cells from P2X7R−/− mice had significantly higher resorbing osteoclasts (5 vs 13 resorbing osteoclasts, p =0.010) and higher resorption but no change in resorption capacity. In oestrogen deplete conditions, despite an overall increase in osteoclast numbers and resorption similar to BM cultures, the fold change in the number of spleen derived osteoclasts was significantly lower (20.3 vs 72.3 fold, p =0.011) as was resorption (32 fold vs 396 fold p =0.0006) in P2X7R−/− compared to P2X7R+/+ mice. This data suggests that the increased osteoclast activity in vitro following oestrogen deficiency is via enhanced cell numbers with the P2X7R modulating the effect further. The extent of the effect is dependent on the origin of osteoclasts. These results may help explain the recently demonstrated association between accelerated bone loss in postmenopausal women with a reduced or non-functional P2X7R.
POSTERS
1.c
Transcriptomic profiling of the four adenosine receptors in human leukocytes of heart failure patients Adenosine is a potent extracellular messenger produced in high concentrations under metabolically unfavorable conditions. Adenosine restores tissue homeostasis through the interaction with its membrane receptors (A 1 R, A 2a R, A 2b R, A 3 R), acting as a retaliatory metabolite. The aim of this study was to evaluate the transcriptomic profiling of ARs in human leukocytes of HF patients as a function of clinical severity and the possible changes with respect to healthy subjects (C). Total RNA was extracted from leukocytes of C (n =8) and of HF patients (NYHA I-II n =9; NYHA III-IV n =14) with a PAXgene Blood RNA Kit. mRNA expression levels of each ARs was measured by Real-Time PCR following reaction conditions optimization. Based on recent guidelines three candidate reference genes (TOP2b, YWHAZ and SRP14) were selected to normalize mRNA expression data. An increase for each ARs (see Table 1 ) was observed as a function of clinical severity. To evaluate the catalyzation of the dephosphorylation of adenine nucleotides to adenosine in the extracellular space, the two cell surface molecules CD39 and CD73 were also evaluated and their transcript and resulted up-regulated. Significant correlations were observed between all ARs themselves. These findings show that components of adenosine metabolism and signalling are altered to promote adenosine production and signalling in HF patients. The increased expression of these ARs appears related to the severity of the disease, as indicated by the progressive rise in mRNA expression values with worsening of symptoms emphasizing a possible AR co-regulation. The increased CD39 and CD73 transcript levels suggests a protective CD39-CD73-dependent adenosine production in advanced HF patients. These data provide proof of the concept that adenosine-based drugs may play a role in the treatment of HF patients after confirmation by randomized clinical trials. There is growing interest in elucidating the mechanisms by which adenosine receptor activation influences inflammatory processes since the adenosine receptors and their downstream signaling pathways are promising targets for new anti-inflammatory therapies. Adenosine levels rise during inflammation and modulate inflammatory responses by engaging with four different G protein-coupled receptors. It is suggested that adenosine exhibits proinflammatory effects through its A1 receptor (A1R), and anti-inflammatory effects through A2A receptor (A2AR). The therapeutic potential of adenosine-related compounds for controlling intestinal motility and inflammation, prompted us to investigate further the role of the adenosine receptors in the gut. We tested selective receptor agonists and antagonists on inflammation-induced morphological disturbance and ACh-induced contraction as well as gene expression of the pro-inflammatory cytokines TNFα and IL-6. An in-vitro inflammation model was used to prove anti-inflammatory effects of adenosine receptor ligands. The mRNA of the four adenosine receptors was found in rat colonic preparations with the highest gene expression for the A2BR. Incubation with the A2AR agonist CGS 21680 (10 μM) normalized inflammation-induced morphological disturbances, cytokine gene expression and to a lesser extent the disturbed motility but had no effect on the inflammation-induced reduction of the ACh-induced contractions. The A2AR antagonist SCH 442,416 (10 μM) itself had no effect on morphological changes after TNBS incubation but antagonized the effects of CGS 21680 (10 μM). Blockade of the A2BR by PSB1115 had no effect on morphological damages and did not change the up-regulated cytokine gene expression. However, PSB 1115 normalized concentration-dependently the disturbed ACh contraction. After induction of inflammation with TNBS, the application of the A2BR agonist BAY 60-6583 reduced ACh contractions indicating the functionality of the A2BR in inflamed preparations. Neither activation nor blockade of A1R (CPA; DPCPX) or A3R (IB-MECA; MRS 1220) had significant influence on TNBS-induced morphological disturbances, cytokine gene expression and disturbed motility. It seems that these two receptor subtypes are not involved in regulation of inflammatory processes on rat colonic preparations. The results presented herein consolidate and expand the current understanding of adenosine receptor distribution and function in the rat colon, and should be taken into consideration for data interpretation regarding the pathophysiological implications of adenosine on intestinal motility disorders. Additionally, the results represent novel therapeutic targets for attenuating multiorgan failure and critical illness within the gastrointestinal tract like irritable bowel syndrome. Whereas the therapeutic approaches are currently being investigated in cell culture models or in isolated rat preparations, we are optimistic that at least some of these novel targets or specific ligands of the adenosine receptors can be translated from bench to bedside in the future.
1.e Purinergic ion channels in mouse spermatogonia
Patricia Almeida Machado*, David Fleck*, Sophie Veitinger, Thomas Veitinger, Susanne Lipartowski, Corinna Engelhardt, Jennifer Spehr, Marc Spehr Dept. Chemosensation, Institute for Biology II, RWTH Aachen University, Germany *These authors contributed equally to this work.
Spermatogenesis is a fundamental and highly complex biological process that ensures male fertility. Spermatogonia are the precursors of all male germ cell stages. Their differentiation assures the lifelong production of mature sperm. However, few physiological details are known about testicular cell communication during spermatogenesis. As we and others have previously shown that Sertoli cells are able to communicate via ATP, we hypothesize a general role for purinergic signaling in the testis. Using wildtype C57BL/6 mouse pups, we first developed a coculture of Sertoli cells and spermatogonia. Next, we investigated ATP − dependent signaling by whole − cell patch − clamp recordings from cultured spermatogonia. Involved ion channel subtypes of the P2X receptor family were then identified by pharmacological profiling and gene expression knockdown. Here, we report that cultured spermatogonia respond to extracellular ATP (1 -100 μM). ATP − induced currents show fast activation and moderate desensitization. The currentvoltage relationship reveals strong inward rectification. Current potentiation by ivermectin and inhibition by an acidic extracellular pH (6.3) indicate a functional role of P2X4 receptors. Interestingly, an increased ATP concentration (1 mM) activated an additional current with different kinetics, likely mediated by the low sensitivity P2X7 receptor. Knockdown of P2X4 expression significantly attenuated sensitivity to ATP concentrations ≤ 300 μM. Combined with molecular evidence, our results indicate that at least two different of P2X receptor subunits (P2X7 and P2X4) are functionally expressed in spermatogonia of young prepubertal mice. Downstream P2X receptor activation, a slowly activating calcium − dependent potassium current represents a functional antagonist of the depolarizing P2X receptors. Together, these data represent a first important step towards a deeper understanding of cellular purinergic communication during spermatogenesis. Extracellular nucleotides such as adenosine-5′-triphosphate (ATP) serve as important signals in many biological processes and is released by many immune cells during an inflammatory response. The binding of T Cell Receptor to the ligand triggers a cascade of signals resulting the release of calcium from intracellular stores and the opening of Calcium Release Activated Channels to promote the subsequent activation processes. The increased concentration of cytosolic free calcium and mitochondria uptake lead to the synthesis and release of ATP by T lymphocytes via pannexin-1 hemichannels. Many studies now show that autocrine ATP signalling via purinergic receptors is vital to sustain and promote T cell activation. We report that ATP can also signal in a paracrine manner between CD4+ lymphocytes and trigger calcium waves in murine ex vivo lymph node slices. Using a series of of pharmacological agents and shRNA, we identified P2X4 and P2X7 as the key purinergic receptors for paracrine ATP signalling. Extracellular ATP disrupts lymphocyte chemotactic migration in vitro, and acts as a paracrine messenger to reduce the motility of lymphocytes ex vivo. This may represent an additional mechanism contributing to the orchestration of cell trafficking in lymph nodes.
1.f Paracrine ATP signalling between T lymphocytes
1.g Cellular uptake of metal ions by osteoblasts -a possible role for P2X7 receptors?
Karan M. Shah, J. Mark Wilkinson, Alison Gartland The Mellanby Centre for Bone Research, The Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK Local joint tissue and systemic concentrations of cobalt and chromium are persistently elevated after metal-on-metal hip resurfacing. We have previously shown that clinically relevant metal ion concentrations metal ions enter human osteoblast cells (SaOS-2) adversely affecting their survival and function. The mechanism of cellular entry of these ions remains unclear although a role for several putative transporters and receptors including P2X7R has been implicated. It has been suggested that Co and Cr may result in ATP release from cells to activate P2X7R and mediate cellular entry (Bhabra G, et al. Nat Nanotechnol 2009; 4(12):876-83). In this study we investigated the role of P2X7R in real-time uptake of Co 2+ at different concentrations. Human osteoblast (SaOS-2) cells were cultured in 48 well plates and loaded with 0.25 μM Calcein AM, a fluorescent compound which is quenched in presence of Co 2+ at 37˚C for 15 min. Excess indicator was washed-off and cells were incubated for a further 30 min with or without 40nM P2X7R antagonist (A740003). Cells were imaged using Leica AF6000 Time-Lapse imaging system for 1 h with images taken every 2 min. Co 2+ (0, 0.1, 1, 10, 100 and 1000 μM) was added to wells after 4 min which served as baseline. Images were analysed using ImageJ. Results show a lower quenching of fluorescence in cells treated with P2X7R antagonist with the area under the curve being significant higher for 0.1 μM (P <0.01), 10 μM, 100 μM and 1000 μM (P <0.0001). This suggests reduced cellular entry of Co 2+ in antagonist treated cells. This study demonstrates a role of P2X7R in cellular uptake of metal ions in the periprosthetic environment and a potential therapeutic target to ameliorate local toxic cellular effects.
1.h
The expression of adenosine receptors mRNA in human leukocytes. A study on patients with advanced valvular disease undergoing cardiac surgery Purpose: Adenosine is a retaliatory metabolite acting as a potent anti-inflammatory autacoid; it is defined as a "danger signal" for cells and organs. Extracellular ATP is generally released in conditions of injury or stress and it is dephosphorylated to AMP by the ectonuclease triphosphate diphosphohydrolase (CD39), followed by degradation to adenosine by the ecto-5′-nucleotidase (CD73). Adenosine mediates its cellular functions by four specific transmembrane receptors (A1R, A2aR, A2bR and A3R). In different animal models an up-regulation of specific adenosine receptors (ARs) has been documented in cardiac tissue during heart failure (HF). Recently ARs mRNA expression has been assessed in human whole blood. The aim of this study was to study the possible changes of mRNA expression profile of A1R, A2aR, A2bR and A3R in human leukocytes of patients (pts) with valvular HF (Vlv) as compared to healthy subjects (C). Methods. Total RNA was extracted from leukocytes of C (n =7) and of Vlv pts before cardiac surgery (n =6, NYHA III-IV) with PAXgene Blood RNA Kit (Qiagen, Milan, Italy). These extracts were retrotranscripted to cDNA, then Real time PCR analysis was performed and optimized for each ARs primer. CD39 and CD73 mRNA expression was also evaluated both in C and in Vlv pts. The experimental results were normalized with the three most stably expressed genes (SRP14, EEF1A, RPL13A). Results. In human whole blood of Vlv pts significantly higher levels of mRNA expression were observed in each receptor with respect to C (A1R: C = Conclusions. An increase of AR mRNA expression in the peripheral circulating cells of Vlv pts undergoing cardiac surgery was documented, suggesting a protective CD39-CD73-dependent adenosine production in Vlv pts in advanced NYHA classes. The approach on human leucocites allows the assessment of ARs transcriptomic profiling in HF; a potential application of this method for monitoring the response to treatment can be foreseen in HF, a pathology still burdened by high mortality and morbidity.
1.i Expression profiling of purinergic signaling molecules on T cells in acute lung injury
Tao Yang Inflammatory mechanisms play a crucial role in the pathogenesis of acute lung injury (ALI) in which extracellular nucleotides and nucleosides, particular ATP/NAD and its metabolites, have been implicated as important signaling molecules. The ectoenzymes CD39 and CD73 are widely expressed on immune cells and promote the degradation of extracellular nucleotides to anti-inflammatory adenosine. Adenosine has been shown to inhibit T cell activation and this may critically impact the late phase of inflammation.
In this study the changes in the expression of multiple purinergic signaling molecules were assessed in different T cell subsets after acute lung injury. For induction of ALI female mice were anaesthetized, orally intubated and challenged with intra-tracheal instillation of 3 μg/g LPS dissolved in 60 μl of saline. After 3 days and 7 days of LPS treatment, blood, lung tissue and bronchoalveolar lavage (BAL) was collected. Immune cells were isolated and analyzed using flow cytometry. To assess the transcriptional phenotype of different T cell subsets from lung tissue, T-helper cells, cytotoxic and regulatory T cells were sorted using FACS. RNA was extracted and reverse transcribed and finally the expression profile of about 30 genes including ectoenzymes, ATP and adenosine receptors and transporters was determined using TaqMan® Array Micro Fluidic Cards. Catabolism of the nucleotides ATP and NAD to different metabolites by CD4 positive T cells was evaluated via HPLC. Under basal unstressed conditions lymphocytes represented the predominant cell type in the blood and lung tissue while in the BAL, alveolar macrophages were the most prominent fraction. CD39 and CD73 on myeloid and lymphoid cells in the blood and lung tissue showed an opposite expression pattern: high expression of CD39 on myeloid cells and a low expression on lymphoid cells. In contrast, CD73 was highly abundant on lymphoid cells but less expressed on myeloid cells. After 3day of injury, granulocytes, macrophages and antigen-presenting cells were substantially increased in all 3 compartments, whereas T cell subsets were enhanced only in the later phase of inflammation. Interestingly, the abundance of CD39 and CD73 was significantly increased on T cells derived from lung tissue and BAL after lung injury. Furthermore, the different T cells subsets in lung tissue showed distinct changes in the expression pattern various purinergic signaling molecules after LPS challenge. The activity of ATP, ADP, AMP and NAD degrading enzymes was confirmed by the chromatographic analysis. Our study demonstrates that LPS-induced ALI significantly modulates the expression profile of molecules involved in purinergic signaling pathways in different T cell subsets. These phenotypic changes observed are likely to contribute to the resolution of the inflammatory process associated with ALI. Our data provide new insights into the pathogenesis of ALI and may reveal new potential targets for therapeutic approaches. # Both authors contributed equally to this work. Since the role played by adenosine and its receptors is still unclear in these cells, we started our investigation aimed at evaluating the presence and the effects of the stimulation of A 1 R on the proliferation and/or the adipogenic differentiation of adipose mesenchymal stem cells (AMSCs) isolated from human SAT. Cytofluorimetric analysis revealed that undifferentiated AMSCs expressed numerous stemness markers, including CD73/ecto-5′-nucleotidase, whereas real-time PCR assay showed that the four P1 adenosine receptors are expressed by these cells. Focusing on A 1 R, we also found that when AMSCs were grown in adipogenic medium, the expression of A 1 R gradually increased along the differentiation process. The exposure of undifferentiated AMSCs to full or partial A 1 R agonists, added to cells at each medium change, restrained the proliferation of these cells at the days 4 and 8 from the beginning of the experiments, as assessed by MTS assay. In contrast, in cells submitted to adipogenic differentiation and exposed to full or partial A 1 R agonists, the proliferation was slightly increased, again at the days 4 and 8. Surprisingly, purine compounds, mainly A 1 R partial agonists at the highest assayed doses, caused also a reduced fat droplet accumulation, evident after 35 days of adipogenic differentiation, as measured by Oil Red Oil assay. Real-time-PCR analysis showed that this effect was preceded by a decreased expression of PPARγ and FABP4, both factors being considered as the main initiators of the adipogenic process. Our findings are partly in contrast with data obtained by other research groups using, however, cells deriving from other kinds of tissue to differentiate into adipocytes [Gharibi B. et al., Int. J. Obesity 2012; 36: 397-406] . In our opinion, our data encourage the research on A 1 R as possible target in the management of obesity and diabetes and may have clinical implications in the treatment of these human diseases. Cells expressing the proteoglycan NG2 are multipotent neural progenitors with lineage plasticity able to primarily generate myelinating oligodendrocytes. They are also known as oligodendrocyte precursors cells (OPCs), are the only slowly proliferating cells in the adult brain, and react to injury. Under some circumstances, they can also generate neurons (Kondo & Raff, Science 289:1754 , 2000 ; however, this first sensational paper showing that NG2 cells can be reprogrammed to neurons was followed by only few in vitro (Liu et al., J Neurosci 27:7339, 2007 ) and in vivo confirmations (Richardson et al., Neuron 70:661, 2011) . The latter study suggests that NG2 cells lineage plasticity may be markedly widened by insults and epigenetic agents that profoundly change their reactivity and the surrounding local mileu. Previous studies from our laboratory have identified the purinergic receptor GPR17 as a new marker of early stages of NG2 cell differentiation, showing that GPR17 activation accelerates NG2 cells' oligodendrocyte fate (Fumagalli et al., JBC 25:10593, 2011; Ceruti et al., Glia, 59:363, 2011; Boda et al., Glia 59:1958 . Based on these premises, aim of this work is to unveil the stem cell properties of NG2+ precursor cells and to induce their differentiation towards a neuronal lineage, also through the modulation of the GPR17 receptor. Primary OPCs from the cerebral cortex of P2 rat pups were kept in culture for 6-8 days as mixed astrocytes-OPCs cultures and purified by vigorous shaking of flasks, and immunopanning selection. OPCs have been then cultured accordingly to two published protocols (Kondo & Raff, 2000; Liu et al., 2007) both able to unveil their stem cell properties. In either protocol, we have verified if and how the exposure to various pharmacological agents (including GPR17 receptor ligands) can modulate OPCs plasticity and their differentiation to neurons. In particular, we have utilized the non-selective GPR17 agonist UDP-glucose (10 μM) and antagonist cangrelor (10 μM), in parallel to the anticonvulsant agent valproic acid (VPA, 500 μM). VPA is known as an epigenetic modulator, which inhibits histone deacethylases (HDAC) and consequently induces transcription changes which favor neurogenesis (Yu et al., Neuropharm 56:473, 2009 ). In both culturing conditions, we observed an increase in the percentage of cells expressing the neuronal marker β-tubulinIII (βtubIII) upon treatment with cangrelor and VPA with respect to control. Interestingly GPR17, which is normally expressed only by NG2+ cells, was surprisingly detected in a subset of βtubIII + cells already under control differentiative condition, suggesting its potential involvement in neurogenesis. The appearance of this cell population was further incremented by the exposure to VPA and cangrelor, and slightly reduced by UDP-glucose, which likely promotes receptor down-regulation and drove NG2 cell specification towards a "classical" oligodendrocyte fate. Taken together, our results suggest that antagonizing GPR17 functions can address the fate of NG2 cells towards the generation of new neurons, as observed with epigenetic modulators like VPA. We are currently testing whether a combination of the two agents may further enhance the neurogenic shift of NG2 cells, a paradigm that could be exploited in neuroregeneration in vivo.
2.b
Postnatal neural progenitor cells express functional P2X7 receptors in the dentate gyrus . We used transgenic Tg(nestin/EGFP) mice to identify their hippocampal NPCs in brain slices. Whole cell patch-clamp recordings showed inward currents after the application of ATP (3000 μM) and dibenzoyl-ATP (BzATP; 300 μM) near the resting membrane potential (−80 mV). The BzATP currents reversed at about 0 mV, corresponding to the reversal potential of non-selective cationic currents. BzATP was more potent than ATP itself and the activities of both agonists increased in a low Ca 2+ and zero Mg 2+ artificial cerebrospinal solution, suggesting the involvement of P2X7 receptors. This idea was supported by the concentration (1 μM, 10 μM)-dependent inhibition of the agonist-induced currents by A-438079 a selective P2X7 receptor antagonist. The BzATP-evoked currents were not altered in the presence of NMDA-, AMPA-, GABA A -receptor antagonists (AP-5, CNQX, gabazine) and tetrodotoxin, a blocker of voltage-dependent sodium channels. Thus, the currents are caused exclusively by the stimulation of P2X7 receptors. Excised patches were prepared by slowly withdrawing the patch pipette from the whole-cell recording configuration and thereby isolating them from the surrounding tissue; these patches still reacted to BzATP, although with a decreased current amplitude. We suggest that the apoptotic/ necrotic P2X7 receptors in NPCs may be of particular relevance during pathological conditions, such epileptic seizures that lead to an increase of extracellular ATP levels and thus could counterbalance excessive seizure-induced cell proliferation in the hippocampal dentate gyrus. benzene propanoic acid). CGS21680 decreased delayed rectifier outward K + currents (I K ) in a concentration-dependent manner (1-100 nM, n = 21) and did not modify transient outward K + currents (I A ). At 100 nM the reduction was from 267.6±44.6 pA/pF to 191.9±39.5 pA/pF (n =8; P <0,01). The CGS21680 effect on I K currents was reversed by the selective A 2A R antagonist SCH58261 (2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo [4,3-e] [1, 2, 4] triazolo [1,5-c] pyrimidin-5-amine, 100 nM, n =8) and by the I K blocker TEA (tetra-ethyl-ammonium, 3 mM, n =5). I K currents are known to be involved in OPC development, since their block decreases OPC proliferation and differentiation (Gallo et al., J. Neurosci. 16: 2659 -2670 , 1996 . On these basis it was tested whether A 2A Rs modulate these processes. CGS21680 (100 nM), directly applied in the culture medium of oligodendrocytes, reduced cell differentiation as evaluated at 3; 6; 9 days by immunocytochemical labeling of specific maturation markers (NG2 proteoglycan, O4 antigen and MAG glycoprotein), without affecting cell proliferation, as evaluated by BrdU incorporation assay. The CGS21680-induced reduction of OPC differentiation was prevented by SCH58261 (100 nM ] i ) transients were recorded by the whole-cell patch clamp technique and the fura-2 method, respectively. Four types of NPCs could be identified according to their voltage-current characteristics and spiking behaviour. Whereas all investigated NPCs uniformly exhibited only very small current responses to ATP or the more selective P2X7 receptor agonist dibenzoyl-ATP (BzATP) in a normal superfusion medium, their current amplitudes largely increased in a low Ca 2+ -containing, Mg 2+ -free medium. Concentration-response curves of the two agonists revealed a higher potency for Bz-ATP than for ATP itself. The Bz-ATP-induced currents measured at holding potentials between −80 and +60 mV reversed polarity near 0 mV, in accordance with the opening of a non-selective cationic channel. The P2X7 selective antagonists Brilliant Blue G and A-438079 blocked the ATP effects; NPCs prepared from P2X7 −/− mice did not respond to ATP or BzATP. Long-lasting applications of Bz-ATP induced an initial current, which slowly increased to a steady-state reponse. In combination with the determination of YO-PRO uptake, these experiments suggest the dilation of a receptor-channel and/or the recruitment of a dye-uptake pathway. The ionotropic glutamate receptor agonists AMPA and NMDA were without effect; the GABA A receptor agonist muscimol caused only small current responses. These data suggest that ionotropic receptors for glutamate and GABA are absent at NPCs, accentuating the significance of ATP-sensitive signalling at undifferentiated proliferating neural progenitors. Measurements of Ca 2+ transients in a normal Ca GPR34 is an orphan G protein-coupled receptor which is highly conserved among vertebrates. Phylogenetic studies have assigned this receptor to the group of P2Y 12 -like receptors. As ligand for GPR34 lysophosphatidylserine was published (Sugo et al., Biochem Biophys Res Commun. 341:1078 -1087 . 2006 ) but seems only to act as surrogate ligand in our hands. By screening a nucleotide library for potential ligands, EDA-ATP could be identified as antagonist for GPR34 (Ritscher et al., Biochem J. 443: 841-850. 2012) . The receptor has a ubiquitous expression pattern and qPCR analysis revealed highest expression in the CNS, specifically in microglia. Preliminary studies on a GPR34-deficient mouse model showed significantly increased basal cell swelling of retina and Müller cells and a higher pathogen burden in spleen, lungs and brain after pulmonary infection with Cryptococcus neoformans when compared to wildtype (WT) mice (Liebscher et al., JBC 286: 2101 -2010 ). These and additional evidences indicate a role of GPR34 in immune functions. Because little is known about the relevance of GPR34 in the brain, we focused on comparing the knockout (KO) strain with WT mice concerning various CNS functions. Bedard et al. (Glia 55:777-789. 2007 ) identified GPR34 among other genes as one marker gene for microglia based on its high expression level. Treatment of microglia with lipopolysaccharide resulted in a robust decrease of GPR34 mRNA expression. To identify the role of this P2Y 12 -like receptor on microglia function, microglial cells were analysed in morphometric, flow cytometric, migration and phagocytosis tests. Comparing the number of microglia in the hilus region in brain slices, KO mice had an increased number of microglia related to WT mice. Further, the microglial morphology was altered in KO mice presenting a more compact and larger soma and less branching per cell. Capability to migrate into damaged tissue was analysed with an entorhinal cortex lesion model and no differences in invading microglia number were found. Another important function of microglia is the ability to phagocytose. We found that the phagocytic activity of microglial cells was lower in GPR34-deficient mice when compared to WT both in the retina and in acutely isolated slices from cortex.
2.c
3.b Functional characterization of the orphan receptor GPR171
Antje Brüser, Angela Schulz, Torsten Schöneberg Institute of Biochemistry, Medical Faculty, Johannisallee 30, 04103 Leipzig GPR171 is an orphan G protein-coupled receptor (GPCR) and belongs to the P2Y 12 -like receptor group within the family of rhodopsin-like receptors. Phylogenetically, this group includes the ADP receptors P2Y 12 and P2Y 13 , the UDP-glucose receptor P2Y 14 and the orphan receptors GPR34, GPR87, GPR82, and GPR171 (Schöneberg, T., et al., Purinergic Signal 3, 255-268, 2007) . Very little is known about the physiological function of these members, besides P2Y 12 with its central role in platelet aggregation and being the therapeutic target of clopidogrel (Foster C. J. et al., J Clin Invest 107, 1591 -1598 , 2001 Hollopeter, G. et al. Nature 409, 202-207, 2001 ). GPR171 was identified in different vertebrates and has been conserved over the past 450 Ma. It appears to be a highly relevant receptor for vertebrate physiology, because by comparison of 60 orthologs no GPR171-deficient vertebrate has been identified yet. The human and mouse GPR171 are located on chromosome 3 clustering with P2Y 12 , P2Y 13 , P2Y 14 , and GPR87 (3q24-25). However, it is not clear whether nucleotides are agonists of GPR171. Quantitative PCR analyses in mice showed GPR171 expression in all tissues specifically in peripheral and nervous central immune cells. Treatment of microglia and astrocytes with lipopolysaccharide resulted in a down-regulation of GPR171 in these cells. In vitro studies revealed Gα i -protein coupling and adenylyl cyclase inhibition. Screenings of compound libraries for GPR171 ligands were performed and in-depth mutagenesis studies served to investigate structure function relationships.
3.c Adenine receptor activation -novel aspects during hypoxia
Bloßfeld Mark Cerebral hypoxia is a multifactorial process that often results in mortality and morbidity. Neurons are highly susceptible to a deprivation of oxygen and glucose and therefore a loss of function and cell death can be observed within minutes after a hypoxia occurs. Due to inadequate therapeutic opportunities and a limited time frame, novel options of treatment are needed. A novel target could be the recently discovered adenine receptor, a new class of G proteincoupled purinergic receptors. There is limited profound knowledge of its physiological function, signalling pathways or its relevance during pathophysiological processes. Here we assessed the effect of adenine receptor activation on neuronal function during hypoxic (1 % O 2 ; 5 % CO 2 ; 94 % N 2 ) conditions. First, the adenine receptor should be detected on rat neuronal cells. Afterwards intracellular recordings were performed on cortical pyramidal cells in rat brain slices to investigate the influence on the amplitude of electrically evoked postsynaptic potentials (PSPs). Additionally investigations were done to reveal a possible signalling pathway of the adenine receptor using cytotoxicity assays on rat neuroblastoma cells (B104) and intracellular recordings. The adenine receptor was detected in rat cortical slices as well as on B104 neuroblastoma cells. In rat brain slices adenine (10 μM to 1 mM) depressed concentrationdependently the PSP amplitude, but had no effect on membrane potential and input resistance. Exposure to hypoxia (5 min) resulted in a depressed PSP amplitude. The reduction was mediated by endogenous adenosine and was completely abolished by adenosine deaminase. Superfusion with adenine (1 mM), 5 min to the onset of hypoxia, diminished the hypoxia-induced effect on the PSPs. Hence, an interaction of the adenine receptor with the adenosine A 1 receptor was postulated and could be confirmed by experiments, in which adenine reduced the effects of the adenosine A 1 receptor selective agonist N6-Cyclopentyladenosine (CPA; 100 nM). Comparable to hypoxia, CPA decreased the PSP amplitude. Adenine (1nM to 10 mM) concentration-dependently reduced cell viability and increased cell death in B104 neuroblastoma cells. Co-incubation of N-ethylmaleimid (NEM 3 μM), an inhibitor of pertussis toxin sensitive G proteins, with adenine (1 mM), did not influence the effects of adenine. Thus, a coupling of the adenine receptor to a G i protein, as described before, could not be confirmed in our experimental design. Our results point out that during hypoxia adenine modulates synaptic transmission by interaction with the adenosine A 1 receptor. Whether this effect is neurotoxic remains unclear. Further our investigations show that besides the described G i protein-coupled adenine receptor other subtypes, for example a G q protein-coupled adenine receptor, exists. The P2X7 receptor (P2X7R) subtype is an unusual member of the ATP-gated P2X receptor family. In contrast to other P2X receptors, it requires high concentrations of ATP for opening and its prolonged activation results in the formation of membrane pores permeable to large molecules such as fluorescent dyes. The receptor is expressed in cells of the hematopoietic lineage as well as endothelial and epithelial cells and has been shown to play a crucial role in inflammatory processes. Various studies suggest a role in neuroinflammatory and neurodegenerative diseases, but the underlying mechanisms remain unclear. To study the physiological and pathological function of P2X7R in vivo, we have generated BAC transgenic mice overexpressing the mP2X7R fused to a Strep-His-EGFP reporter under the control of the endogenous P2X7 promoter on a FVB/ N background. Genetic, biochemical, and immunohistochemical analyses revealed that the four transgenic lines obtained differ in the amount of inserted gene copies, resulting in up to 4-fold overexpression of the P2X7R protein. All lines show an identical expression pattern in the brain, with predominant expression in molecular layers in the cerebellum. Mice from the strain with highest overexpression, X7GFP-61, develop clear motor deficits already at a very young age. A systematic analysis of the motor phenotype is currently prepared. In conclusion, the mP2X7-EGFP mouse model provides a novel promising tool to identify the localization of P2X7R in specific cell types and to investigate its physiological and pathological roles in the central nervous system.
3.d Pathophysiological analyses of BAC mP2X7-EGFP transdenic mice
3.e Gene regulation of the P2Y-like receptor GPR17 in oligodendrocytes, and pathological alterations in a mouse model of multiple sclerosis The P2Y-like receptor GPR17 is a G protein-coupled receptor activated by uracil nucleotides and cysteinyl-leukotrienes and we have previously demonstrated that it is a key regulator of oligodendroglial differentiation. Under physiological conditions, the receptor starts to be expressed in oligodendrocyte precursor cells (OPCs) also positive for the early marker NG2, it reaches a peak of expression in immature oligodendrocytes, and it is progressively downregulated during terminal maturation (Lecca et al., 2008. PLoS One. 3:e3579; Fumagalli et al., 2011. J Biol Chem . 286:10593-604) . At early differentiation stages, GPR17 activation with agonists induced, while inhibition with antagonists or specific interfering RNAs impaired OPC maturation. At later stages, the forced GPR17 overexpression also led to impaired maturation. All these data suggest that the expression of the receptor GPR17 needs to be time regulated either at transcriptional, or post-transcriptional level. The present work was aimed at understanding what is the molecular mechanism at the basis of Gpr17 gene expression, and to assess if receptor expression is altered in spinal cord of mice with the experimental autoimmune encephalomyelitis (EAE), a widely used model of demyelinating disease. To answer to the first issue, we cloned a putative promoter region of the Gpr17 into a reporter vector upstream to the firefly luciferase gene; then, we transfected this construct in Oli-neu cells, an immortalized oligodendroglial cell line, and we set up a dual luciferase reporter assay to evaluate the bioluminescence produced in response to an array of stimuli, including nucleotides, hormones and growth factors. Interestingly, incubation of cells with conditioned medium from cortical neurons significantly induced Gpr17 promoter activity (Fratangeli et al., 2013 . J Biol Chem . 288:5241-56), but we still don't know which is the released factor responsible of this effect. Signals released by axons can profoundly influence the expression pattern of oligodendrocytes, and this is responsible of their behaviour both in physiological and in pathological conditions. For this reason, we assessed the expression of GPR17 in mouse spinal cord in EAE. As already described for brain, immunohistochemical analysis revealed that, also in spinal cord, GPR17 specifically decorates a subset of OPCs both in grey and white matter. After EAE induction, both the total number of CC1-positive (representing the maturing oligodendrocytes) and GPR17-positive cells was reduced, whereas the number of NG2-positive cells was increased, suggesting disease-induced recruitment and proliferation of early progenitors. Interestingly, qRT-PCR showed that the mRNA of GPR17 is increased in EAE, and this seems to be in relation with the clinical score of the mice.
We hypothesize that, as demonstrated in brain ischemia, the expression of GPR17 is up-regulated in the disease to counteract demyelination, but this response is insufficient and may lead to dysregulations contributing to the disease. Understanding how the expression of GPR17 is finely regulated will not only advance basic knowledge in oligodendrogliogenesis, but will also help developing new strategies to enhance the reparative potential of the quiescent OPCs that are still present in the adult brain. In recent years, evidence indicated that adenosine A 2A receptor subtype is of critical importance in stroke (Chen and Pedata,Curr Pharm Des. 14: 1490-9, 2008 ). An overexpression of A 2A adenosine receptors occurs at central level on neurons and microglia of ischemic striatum and cortex after focal cerebral ischemia (Trincavelli et al., J Neurochem 104: 479.90, 2008) . Adenosine A 2A receptor subtype is localized not only at central level but also peripherally on leukocytes, where they are known to exert antinflammatory effect (Chen and Pedata, Curr Pharm Des. 14: 1490-9, 2008) . Our previous data demonstrate protection by A 2A agonists, systemically administered, in various models of peripheral (rheumatoid arthritis, colitis, acute lung inflammation) and central diseases such as spinal cord trauma (Paterniti et al., J Neuroinflamm 8: 31, 2011), involving inflammation. Purpose of the present work was to investigate the putative neuroprotective effect of the adenosine A 2A receptor agonist, CGS21680, in the model of transient focal cerebral ischemia in the rat. Cerebral ischemia was induced by occlusion of middle cerebral artery (MCAo) for 1 h. CGS21680 (0.01 mg/kg, i.p.) was administered starting after 4 h from ischemia according to a chronic protocol (twice/day for 7 days). Sensory motor deficit and body weight were evaluated 1, 5 and 7 days after transient MCAo. Seven days thereafter, infarct volume was histologically evaluated and astrogliosis and microgliosis were determinated by immunohistochemical studies (anti-GFAP and anti-IBA1 antibodies, respectively). After 2 and 7 days from transient MCAo, the number of infiltrated blood cells into cerebral ischemic tissue was evaluated by anti-HIS48 antibody (against granulocytes). CGS21680, administered at the low dose of 0.01 mg/kg intraperitoneous, modified neither blood pressure nor heart rate. Following transient MCAo, CGS21680 protected from neurological deficit from the first day up to 7 days thereafter (at 7 day was: 7.00±0.64 n =9 in vehicle group and 4.37±0.90 n =4 in CGS2160 0.01 group; Student's t test: p <0.001). At this time, it reduced the volume of the ischemic cortical damage (75.15±5.13 n =9 in vehicle group and 51.88±10.37 n =4 in CGS2160 0.01 group; Student's t test: p <0.02) and improved the cytoarchitecture of ischemic areas (cortex and striatum) and the myelin organization in ischemic striatum. Seven days after transient MCAo, a strong microgliosis and astrogliosis was observed in ischemic areas, but none granulocyte infiltration was evident. On the contrary, 2 days after transient MCAo, a massive number of infiltrated granulocytes into cerebral ischemic tissue was observed (in cortex: 37.50±6.85 n =3; in striatum: 36.25±17.45 n =3). CGS21680 reduced infiltration in the ischemic areas (in cortex: 20.32±2.41 n =3, Student's t test: p <0.02; in striatum: 27.32±4.22 n =3, ns). This results indicate that adenosine A 2A receptor agonist CGS21680, systemically administered, improves ischemic tissue damage and neurological deficit by an immunosuppressive effect exerted in the first days after ischemia, bringing ultimately to a reduced inflammatory cascade in the ischemic brain area. Enhanced activity of trigeminal ganglion neurons is thought to underlie neuronal sensitization facilitating the onset of chronic pain attacks. Chronicity might establish a neuroinflammatory ganglion profile with inflammatory cells contributing to the hypersensitive phenotype. We first investigated whether, in trigeminal sensory ganglia, cytokines such as TNFα might contribute to a local inflammatory phenotype of a transgenic mouse model of familial hemiplegic migraine type-1 (FHM-1, Cacna1a R192Q knock-in mice). With respect to wild-type, R192Q KI trigeminal ganglia were enriched in activated macrophages and expressed higher mRNA levels of IL1β, IL6, IL10 and TNFα cytokines and the MCP-1. Functional consequences of crosstalk between macrophages and sensory neurons were studied in primary ganglia cultures, in which larger release of soluble factors and larger currents mediated by pain-transducing ATP-gated P2X3 receptors were found. Consistently, we observed that, following LPS injection, TNFα expression and macrophage occurrence were significantly higher in R192Q knock-in ganglia with respect to wild-type ganglia. Our data suggest that the complex cellular and molecular environment of sensory ganglia could support a new tissue phenotype compatible with a neuroinflammatory profile. We propose that, in selected patients, this condition might contribute to pain pathophysiology through release of soluble mediators, including TNFα and ATP that may modulate the crosstalk between sensory neurons and resident glia, underlying the sensitisation process. Supported by Telethon (GGP10082), Cariplo Foundations, ARRS and Crossborder Cooperation Programme Italia -Slovenia grant MINA.
3.g Neuroinflammation in trigeminal ganglia alters P2X3 receptor function
3.h
The selective antagonism of P2X7 and P2Y1 receptors supports the recovery of synaptic activity after oxygen and glucose deprivation in the rat dentate gyrus In the central nervous system, including dentate gyrus (DG), P2X and P2Y receptors are broadly expressed on both neurons and glial cells. In this study we investigated the role of P2 purinergic receptors during oxygen and glucose deprivation (OGD), in the DG. We conducted extracellular recordings of DG field excitatory post-synaptic potentials (fEPSPs) from slices acutely prepared from male Wistar rats (150-200 g body weight). In agreement with our previous results (Maraula et al., Neuropharmacol. 67:511-520, 20 13), in the DG, 9-min OGD elicited an irreversible loss of fEPSP and was invariably followed by the appearance of anoxic depolarization (AD), an unambiguous sign of neuronal damage. The application, before and during OGD, of two selective P2 antagonists, N 6 -methyl-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2179, selective for P2Y 1 receptor, 10 μM, n =21) and Brilliant Blue G (BBG, selective for P2X 7 receptor, 10 μM, n =19) did not modify fEPSP outcome before and during OGD, but prevented AD appearance and allowed a significant recovery of neurotransmission after 9-min OGD, when slices were reperfused in oxygenated, glucose containing, solution (85.0±4.3 % of pre-OGD values in BBG, and 98.7±8.5 % of pre-OGD values in MRS2179, in comparison to 3.9±4.4 %, n =34, found in untreated OGD slices). The effects of 9-min OGD on proliferation and maturation of cells localized in the subgranular zone of DG of slices prepared from 5-bromo-2′-deoxyuridine (BrdU) treated rats were investigated at different times (3, 6 and 24 h) from the end of 9-min OGD. In order to study cell maturation, slices were incubated with an immature neuronal marker, doublecortin (DCX). The number of BrdU + cells in the SGZ was significantly decreased 6 h after OGD (from 23.6±2.7 before, n =14, to 15.5±1.6 after OGD, n =12). This effect was antagonized by MRS2179 (10 μM, n =4) and BBG (10 μM, n =4). Twenty-four hours after 9-min OGD, the number of BrdU + cells returned to control values and an increased arborisation of tertiary dendrites of DCX + cells was observed, indicative of cell maturation. MRS2179 and BBG did not modify the effect of OGD on cell maturation. Data indicate that the selective antagonism of P2X 7 and P2Y 1 receptors exerts a protective effect on neurotransmission, preventing the depression of synaptic activity and AD appearance induced by a severe OGD in the rat DG. Various G protein-coupled receptors (GPCRs) including adenosine receptors and P2Y receptors have been found to assemble to homodimeric or heterodimeric structures, which often results in changes of their functional and pharmacological properties and thus enhances the diversity of GPCR phenotypes (Nakata et al. J Recept Signal Transduct Res, 30, 337-346., 2010) . The homo-and heterooligomeric association of several P2Y receptor subtypes has been analysed by coimmunoprecipitation and quantitative fluorescence techniques such as BRET or FRET (D'Ambrosi et al. BBA, 1768 , 1592 -1599 , 2007 Savi et al. PNAS 103, 11069-74, 2006; Ecke et al., Biochem J. 409, 107-116, 2008; Bush et al., JBC, 282, 19042-19051, 2007) , and occasionally by blue native PAGE (BN-PAGE) (D'Ambrosi et al. BBA, 1768 , 1592 -1599 , 2007 . We have extensively used BN-PAGE to display the oligomeric state of ion channels including P2X receptors (Nicke et al. EMBO J 17, 3016-3028, 1998; Aschrafi et al. JMB 342, 333-343, 2004) , Cys-loop receptors (Haeger et al. 2010; NSMB 17, 90-99, 2010 ) and chloride channels (Fallah et al. Mol Cell Proteomics 10, M110.004697, 2011) . Here, we addressed the question how well the BN-PAGE technique is suited to display the oligomeric state of various P2Y receptors heterologously expressed in X. laevis oocytes or HEK 293 cells. The P2Y receptors were solubilized with digitonin and purified by nondenaturing Ni-NTA or Strep-Tactin affinity chromatography in the presence of iodoacetamide to prevent artificial cross-linking by inter-subunit disulfide bonds. The P2Y receptors were resolved in their 35 S-methionine-labeled total form and their IR800 or Cy5-labeled plasma membranebound form by SDS-PAGE and BN-PAGE immediately after protein purification. The mouse P2Y2 (mP2Y2) receptor and the human P2Y12 (hP2Y12) receptor migrated mostly in the constitutively homodimeric form in the BN-PAGE gel when expressed in X. laevis oocytes consistent with previous findings based on other techniques and mammalian cell lines such as HEK cells, PC12 cells and SH-SY5Y cells. For the mouse P2Y1 (mP2Y1) receptor, the oligomeric state reported by the BN-PAGE varied depending on the expression system used: the P2Y1 receptor was mostly monomeric or dimeric in nature when purified from X. laevis oocytes or HEK 293 cells, respectively. These findings are at odd with previous findings showing that the P2Y1 receptor is constitutively monomeric in nature and dimerizes in the presence of its agonist (Choi et al. JBC 283, 11050-11063, 2008) . Further experiments are needed to evaluate the impact of BN-PAGE in the resolution of the oligomeric structure of GPCR. This project was supported by a grant of the DFG (FOR748, Schm 5369-2). Most P2X receptor (P2XR) subunits are capable of forming not only homotrimers, but also a multitude of heterotrimeric receptor channels consisting of two distinct subunits including for instance P2X1 + P2X2, P2X1 + P2X4, P2X2 + P2X5, P2X2 + P2X3, P2X2 + P2X6. A notable exemption in the P2X family is the P2X7 subunit that appears to interact exclusively with the P2X4 subunit in an unclear manner. This interaction might be of functional importance, because P2X4 and P2X7 are coexpressed in several immune cells. While there is firm evidence for a physical interaction, controversy exists whether the P2X4 and the P2X7 interact with each other as two distinct homotrimers or coassembled within a P2X4/7 heterotrimer (Guo et al. Mol Pharmacol 72, 1447 -1456 , 2007 Nicke BBRC 377, 803-808, 2008; Casas-Pruneda et al. J Physiol 587, 2887 -2901 , 2009 Boumechache et al. JBC 284, 13446-13454, 2009; Weinhold et al. Cell Mol Life Sci 67, 2631 -2642 , 2010 Antonio et al. BJP 163, 1069 -1077 Kawano et al. BBRC 419, 374-380, 2012; Kawano et al. BBRC 420, 102-107, 2012) . To re-examine a possible heterotrimer formation between P2X4 and P2X7, we co-expressed the human variants hP2X7-His-GFPStrepIII and His-hP2X4 as bait and prey, respectively, in X. laevis oocytes. The proteins were purified under non-denaturing conditions using Ni-NTA chromatography or Strep-Tactin chromatography to verify the protein expression and to screen for the presence of co-purified hP2X4, respectively. The resolution of the co-purified proteins by blue native PAGE (BN-PAGE) revealed GFP fluorescence in a protein complex migrating slower and faster than the hP2X4 homotrimer and the hP2X7-GFP homotrimer, respectively. Using the defined oligomers generated by partially denaturing the glycine receptor as a mass marker, a molecular mass was calculated that corresponds to a heterotrimer consisting of two hP2X7-GFP subunits and one hP2X4 subunit. To strengthen this result, we co-purified the His-hP2X4-RFP with hP2X7-His-GFP-StrepIII as prey and bait, respectively. Scanning the BN-PAGE for fluorescence signals revealed an overlay of GFP and RFP fluorescence in a band intermediate between the bands corresponding to the homotrimers of His-hP2X4-RFP and hP2X7-His-GFP-StrepIII, thus providing further evidence for the existing of a heterotrimeric P2X4/7 receptor channel. We would like to thank the Deutsche Forschungsgemeinschaft (FOR748, grants Ma1581/15-1 and Schm536/9-1) for their financial support. 2 Grünenthal GmbH, Global Drug Discovery, Germany P2X receptors are trimeric ATP-gated cation channels that are involved in the fast signal transduction in many cell types. We have provided experimental evidence that Glu167 and Arg290 interact electrostatically within the ATP-binding site of the rat P2X2 receptor, when the channel is in the closed state but not in the open state. We concluded from these results and from homology modeling that the state-dependent salt bridge switching from Arg290/ Glu167 to Arg290/ATP destabilizes the closed state of the receptor and promotes the ionic coordination of ATP in the ATP-binding pocket (Hausmann, Gunther, Kless, Kuhlmann, Kassack, Bahrenberg, Markwardt and Schmalzing. Mol Pharmacol 83, 73-84, 2013) . To further determine structurally important ionic interactions of Arg290, we have analyzed whether the acidic residues Asp82, Glu84 or Glu85 identified by homology modeling to be positioned in the close vicinity of Arg290 form intersubunit ionic interactions with Arg290. Disulfide trapping and biochemical analysis of substituted cysteine residues revealed evidence that Arg290 and each of the residues Asp82, Glu84 and Glu85 are indeed separated by<4.5 Å in the closed state of the rP2X2 receptor. In addition, functional analysis of charge reversal, charge swap and charge neutralization mutants suggests that Arg290 and Glu84 are electrostatically coupled. Whether an ionic interaction triad of Glu84/Arg290/Glu167 is rearranged during the closed-to-open transition of the channel and thus may be involved in channel gating has to be determined.
4.b
hand the approaching of adjacent receptor subunits where beak and dorsal fin and left flipper and dorsal fin approach each other and on the other hand an intra-subunit movement between beak and left flipper of one subunit.
To prove the hypothesis of a potential relevance of the movement for receptor behaviour, we used a mutagenesis-based approach, by creating cysteine mutants of the (h)P2X3R. By introducing two opposing cysteine residues at the supposed inter-and intra-subunit contact sites, we intended to enable the formation of a disulfide bond resulting in immobilization of the receptor in one state of operation. Therefore, we generated two different sets of cysteine double mutants crosslinking adjacent receptor subunits at two varying positions via an inter-subunit disulfide bond and furthermore a pair of cysteine mutants enabling the formation of an intra-subunit disulfide bond. The influence of the inserted disulfide bonds on the functional consequences of ATP binding was measured by whole-cell patch clamp technique on transiently transfected HEK293 cells. We could identify one cysteine double mutant showing an almost complete abolition of receptor functionality within each set of cysteine double mutants cross-linking adjacent receptor subunits. In a second step, we restored the receptor mobility by reversing the disulfide bond formation using the reducing agent dithiothreitol (DTT). The application of DTT resulted in 9 to 24-fold increased currents compared to the non-reduced state, followed by a current decline after DTT washout.
In conclusion, the predicted receptor movement was confirmed by experimental results. We suggest that the inter-subunit disulfide bond either might prevent ATP binding in the nearby agonist binding pouch or affect the conformational change required for ion channel opening.
4.g Probing the putative pocket: Mutagenesis studies at the rat adenine receptor A new family of purinergic G protein-coupled receptors activated by the nucleobase adenine has recently been described, which constitutes at least two different subtypes. (von Kügelgen I et al., Mol Pharmacol 73:469-477. 2008; Thimm, D. et al., Purinergic Signal. DOI: 10.1007 /s11302-013-9360-, 2013 . The first cloned and characterized member of the adenine receptor (AdeR) family is the rat AdeR. (Bender E. et al., Proc Nat Acad Sci USA 99:8573-8578. 2008) . In the present study we took this receptor as a model receptor to analyze its putative binding pocket. Based on a tentative homology model, (Heo J. et al. J Mol Graph Model 26:800-812. 2007; Knospe . et al. Purinergic Signal. DOI: 10.1007 /s11302-013-9355-6, 2013 alignment studies, and structure-activity relationships several amino acid residues were predicted to be part of the putative binding pocket. A set of nine amino acid residues was exchanged for alanine, and the mutant receptors were expressed in Spodoptera frugiperda (Sf9) insect cells. 5.47 , both located at the extracellular half of transmembrane domain 5 were found to be crucial for receptor activation since their alanine mutants did not respond to adenine. Tyr268 7.32 , located at the extracellular end of transmembrane domain 7 appeared to be involved in stabilizing a certain receptor conformation, since at its alanine mutant adenine showed significantly increased efficacy. Furthermore, using a newly developed specific antibody against rAdeRs we were able to show that the extended N-terminal sequence of the rAdeR constitutes a putative signal peptide of yet unknown function, that is cleaved off in the mature receptor. Our results provide important insights into this new, still poorly investigated family of purinergic receptors. Human immune cells such as macrophages and lymphocytes express an ATP-dependent cation channel, the P2X7 receptor (hP2X7R). The hP2X7R is a membrane-bound cation channel, assembled from three identical subunits, each consisting two transmembrane domains flanked by a large N-glycosylated extracellular domain and short intracellular N-and C-terminal tails. Each hP2X7R harbors three intersubunit ATP binding sites as inferred from homology models based on the X-ray structure of the ATP-bound open state of the zebrafish P2X4 receptor (Hattori and Gouaux, Nature 485(2012)). The second transmembrane domain (TM2) has been shown to be involved in the pore opening and ion permeation of P2X receptor channels in general. Here, we applied cysteine scanning mutagenesis on the TM2 of the hP2X7R (K327 to Y358)) to map residues accessible for extracellularly applied sulfhydryl group-modifying reagents. The various hP2X7R cysteine point mutants were expressed in Xenopus laevis oocytes by cRNA injection. Two days later, ATP-dependent currents were recorded using the two-microelectrode voltageclamp technique in the absence or presence of one of several methanethiosulfonate (MTS) reagents including MTSEA, MTSET and MTSES. We found that among residues F328 to Y343 several cysteine substitution mutants near the putative intracellular vestibule were sensitive to the extracellularly applied MTS reagents. Application of MTSEA to oocytes expressing the mutant hP2X7R-V335C increased the ATP-induced current by increasing the open probability of the hP2X7R. This indicates that V335 is involved in ion channel gating. In contrast, application of MTSEA to hP2X7R-S342C resulted in an inhibition of the ATP-induced ion current either by blocking the ion channel pore or by stabilizing the closed state of the channel. Several hP2X7R mutants displayed a membrane voltage-dependent MTSEA reaction presumably resulting from the structure-based localization of the substituted cysteine residue within the electrical field of the membrane. Experiments with MTSEA applied in the absence or presence of ATP were performed to localize the extracellular end of the channel gate. From experiments with MTS reagents of different size and charge, we got information about the extracellular end of the selectivity filter of the ion channel pore. The study was financially supported by grants of the Deutsche Forschungsgemeinschaft (FOR748, Ma1581/15-1 and Schm536/9-1). The A 2A adenosine receptor (A 2A AR) subtype plays an important role in several pathological conditions such as neurodegenerative disorders, drug addition, inflammation, and pharmacological stress; agonists of this receptor subtype are known to regulate myocardial blood flow through vasodilation and immunosuppression (Cristalli G. et al. Curr. Pharm. Des., 14, 1525 -52. 2008 . Presently, various A 2A AR agonists are in preclinical and clinical trials for the treatment of different diseases including inflammatory conditions, which are characteristic of neurodegenerative processes. However, very potent and selective A 2A agonists are still lacking and development of new ligands endowed with high affinity, good bioavailability, and pharmacokinetic properties will be crucial in order to obtain drugs without side effects. Starting from previous results showing that the introduction of an hexynyl or a phenylethylthio chain in 5′-N-ethylcarboxamidoadenosine (NECA) led to compounds endowed with good affinity and moderate selectivity for the A 2A AR (Cristalli G. et al. Curr. Pharm. Des., 14, 1525 -52. 2008 ) and on the basis of molecular modeling studies, the synthesis of NECA derivatives bearing the above mentioned chains in 2-position and a small polar group in N 6 -position was undertaken (General structure, Figure 1 ). The new molecules were synthesized, using a divergent approach, from commercially available guanosine in nine steps. A functional GloSensor™ cAMP assay recently optimized (Buccioni, M. et al. Purinergic Signal. 7, 463-8. 2011 (Burnstock G. Pharmacol. Rev. 58, 58-86. 2006) . Therefore, ligands able to block P2X3 receptor activation could be useful new agents for the treatment of different pain conditions including inflammatory, neuropathic and cancer pain, and migraine. In the search of P2X3 ligands, new purine acyclic-nucleotides, bearing different substitution in the purine ring, were synthesized and found as partial agonists at this receptor (Volpini R. et al., J. Med. Chem., 52, 4596-603. 2009 ). Furthermore, since non-nucleotide benzylic diamino-pyrimidine derivatives were reported to block P2X3 receptors with high potency (Carter D.S. et al. Bioorg. Med. Chem. Lett. 19, 1628 -31. 2009 ), a new series of purine derivatives bearing a substituted benzyl chain (Figure 1 ) was designed and synthesized. Biological evaluation of these new compounds showed they behave as P2X3 antagonists with IC 50 in the low micromolar range, the 9-(5-iodo-2-isopropyl-4-methoxybenzyl)-N 6 -methyl-9H-purine-2,6-diamine (1) being the most potent compound of the series (Lambertucci C et al. Eur. J. Med. Chem. 65C, 41-50. 2013 ). Therefore, with the aim at improving the potency, new purine derivatives bearing different substituents in 6-position were designed and synthesized.
These compounds were evaluated on recombinant rat P2X3 receptors using patch clamp technique. Results showed that they inhibit agonist evoked currents with different potencies, but with lower effect than 1 . Furthermore, compound 1 was evaluated on native P2X3 receptors from mouse trigeminal ganglion (TG) sensory neurons which express also 5-HT and GABA receptors. Results showed that this molecule inhibits 5-HT 3 receptors, positively involved in nociception and pain transduction, hence it might produce an analgesic effect due to the combinatorial block of P2X3 and 5-HT 3 receptors on sensory neurons (Fredholm et al., Pharmacol. Rev. 2011, 63, 1) . Extra-and intracellular adenosine (Ado) and 2′-deoxyadenosine (dAdo) levels are increased in certain diseases, e.g. upon adenosine deaminase (ADA) deficiency. ADA deficiency leads to severe combined immune deficiency (SCID) due to an impairment of T and B cells. (Blackburn et al., Adv. Immunol. 2005, 86, 1) . Besides immune cells other physiological systems, such as lung, kidney, and nervous system are impaired. Some of the effects may be mediated by the activation of adenosine receptors by Ado, and perhaps also by dAdo. Recently DNA-based therapeutic approaches (e.g., gene therapy, DNA-based vaccines) have gained importance. dAdo may be formed as a degradation product of such therapies and cause side effects via adenosine receptor activation. An X-ray structure of the human A 2A adenosine receptor in complex with Ado revealed that the 2′ OH group forms a hydrogen bond with the conserved histidine H278 and a water molecule (Lebon et al., Nature 2011, 474, 521) . Therefore it can be expected that dAdo exhibits lower affinity than Ado for all four receptor subtypes. However, much to our surprise, potency and affinity data for dAdo at all four adenosine receptor subtypes could not be found in the literature, while a complete set of data for Ado determined in a variety of assays has been published. In the present study we therefore determined the affinities and potencies of dAdo in radioligand binding and cAMP accumulation studies at humans and mouse adenosine receptor subtypes and compared the data to those for Ado obtained under identical conditions. Radioligand binding studies were performed in the absence of ADA with thoroughly washed membrane preparations of cells expressing the respective receptor subtype. In radioligand binding studies dAdo showed >300-fold lower affinity than Ado for A 1 , A 2A and A 3 receptors, but only 5-fold lower affinity for A 2B . dAdo did not display any significant subtypeselectivity in humans. In rats it was A 1 -selective. In cAMP accumulation studies conducted with intact cells differences between Ado and dAdo were only moderate dAdo being 4-11-fold weaker than Ado. The discrepancy in binding and functional studies may be explained by differences in metabolism in intact cells versus cell membranes between Ado and dAdo. In conclusion, dAdo can contribute to adenosine receptor-mediated signaling. GPR17 represents the first example of fully characterized "hybrid" GPCR responding to two unrelated families of nonpeptide signaling molecules. It is specifically activated by both extracellular nucleotides and cysteinyl-leukotrienes, which are released abundantly at the site of ischemic or traumatic insult and subsequently activate repair mechanisms (Ciana, P. et al. EMBO J. 25, 4615-27. 2006 ). GPR17 is highly expressed in organs which can typically undergo ischemic damage like the brain, heart, and kidney. In the intact and injured central nervous system, these receptors are expressed by oligodendroglial cells and act as a modulator of their in vivo and in vitro differentiation. Thus, GPR17 may play a crucial role in remodeling/repair events after injury not only in stroke, but also in demyelinating diseases such as multiple sclerosis. We recently reported 2-phenylethynylATP (PF 9) as strong agonist (EC 50 =0.035 nM) and N 6 -methylATP as potent antagonist (IC 50 =144 nM) of GPR17 (Calleri, E et al. J. Med. Chem. 53, 3489-501. 2010 ). In this work, different stable analogues of these nucleotides, bearing an α,β-methylene or β,γ-dichloromethylene functions within the triphosphate chain, were synthesized and tested on GPR17 transfected cells by using an innovative and non-radioactive functional cAMP assay (Buccioni, M. et al. AR [Cappellacci L et al., Bioorg. Med. Chem. 2008, 16, 336] or which are selective for certain signalling pathways (i.e. biased agonists). In our continuously efforts in searching potent and selective A 1 AR agonists, we have identified 5′-chloro-5′-deoxy-N 6 -(±)-(endo-norborn-2-yl)-adenosine (5′Cl5′d-(±)-ENBA) as a potent and highly selective full agonist of human A 1 AR (hA 1 AR (Ki)=0.51 nM, A 3 /A 1 =2530) [Franchetti P et al., J. Med. Chem. 2009 , 52, 2393 . Moreover, 5′Cl5′d-(±)-ENBA showed acute nocifensive effect in the formalin test and anti-neuropathic properties in a model of neuropathic pain, the spared nerve injury (SNI) of the sciatic nerve in mice. Interestingly, 5′Cl5′d-(±)-ENBA did not modify motor coordination and blood pressure or heart rate in unanaesthetized sham and SNI mice [Luongo L et al., Molecules 2012, 17, 13712] . The interesting biological properties of 5′Cl5′d-(±)-ENBA demonstrated that the substitution of 5′-hydroxyl group in adenosine analogues with a chlorine is well tolerated by A 1 AR and 5′-modified adenosine derivatives could be more druggable than 5′-unmodified ones, since normal ribonucleosides may be phosphorylated by adenosine kinases and then by nucleotide kinases to 5′-mono-, 5′-di-, or 5′-triphosphates and subsequently interact with P2Y receptors and/or other biological targets. As a proof of the concept, N 6 /5′-disubstituted adenosine and 2-chloro-adenosine derivatives were synthesized and evaluated for affinity and selectivity at all human adenosine receptor subtypes. Moreover, antinociceptive activity in a formalin test in mice was assayed. The results of these studies will be discussed. Adenosine is an important regulator of homeostasis in brain, heart, kidney and other organs. Modulation of the broad range of physiological functions is due to activation of G protein-coupled receptors which are classified into A 1 , A 2A , A 2B and A 3 . It is widely accepted that adenosine receptors (ARs) could be promising therapeutic targets in many pathological conditions [Baraldi, P.G., et al. Chem. Rev. 2008, 108, 238-263] . Recently, the involvement of A 3 ARs in neuroprotection has been proposed, thus suggesting the investigation of A 3 antagonists as neuroprotective in stroke [Colotta, V., et al. J. Med. Chem. 2007, 50, 4061-4074] . This promising therapeutic application has produced a growing interest, and the present study takes its place into this scenario. Our research group focused on the development of new human (h) A 3 AR antagonists belonging to correlated classes of bicyclic compounds, such as suitably substituted 2-phenylimidazo [1,2-a] pyrazines. Unpublished data indicated that while the 2-phenylimidazo[1,2-a]pyrazin-8-amine was inactive at all four ARs, introduction of aroyl substituents on the 8-amino group moved the affinity towards the hA 3 AR. In order to improve hA 3 AR affinity and selectivity, targeted modifications are performed at position R 2 , R 6 and R 8 . Affinities of the new derivatives at hA 1 , hA 2A and hA 3 ARs, and their inhibitory effects on NECA-stimulated cAMP production in hA 2B CHO cells were determined. Preliminary results suggest that some of the newly synthesized compounds are potent and selective hA 3 AR antagonists, indeed they possess hA 3 nanomolar affinities while they are completely inactive at the other three AR subtypes. The potent and selective hA 3 AR antagonist 2-phenyl-8-bis(benzoyl)amino-imidazo [1,2-a] pyrazine, tested in an in vitro rat model of cerebral ischemia, proves to be effective in preventing the failure of synaptic activity induced by oxygen and glucose deprivation in the hippocampus. Moreover, some selected compounds were evaluated for their fluorescent properties in order to establish their possible utility for pharmacological studies on hA 3 ARs. Adenosine is a neuromodulator that plays important roles for motor function, mood and memory, and coordinates responses to dopamine and other neurotransmitters. Adenosine receptors (ARs) are comprised of four distinct subtypes designated A 1 , A 2A , A 2B and A 3 . Both A 2A and A 1 are highly expressed in the brain, particularly striatum, while A 2B and A 3 receptors are more widely distributed in tissues throughout the body [Fredholm, B.B. et al. J. Pharmacol. Rev. 2001, 53, 527] . Selective A 2A antagonists have been highly sought after that have proved useful in the symptomatic relief of Parkinson's disease (PD), with some reports suggesting that they may also slow disease progression because of their neuroprotective potential. There have been several reports published indicating that adenosine A 1 antagonists may improve learning and memory. This would suggest that dual A 2A / A 1 antagonists may offer improved benefit to PD patients addressing also the cognitive deficiencies associated to the disease [Shook, B. C.et al. ACS Chem. Neurosci. 2011, 2 , 555] . Recently in our laboratory, much effort has been directed toward the design and synthesis of new adenosine receptor antagonists that show either hA 2A selectivity or balanced hA 2A /hA 1 receptor affinity. As a part of this research project, we design new suitable substituted thiazolo [5,4-d] pyrimidin-7-amino derivatives (Series A ) as hA 2A antagonists. Compounds of Series A incorporate elements considered as important structural features for anchoring at the hA 2A recognition site [Cristalli G. et al. ChemMedChem 2007, 2 , 260] . In particular, compounds of Series A bear the 7-amino group and the nitrogen atom at position-1 able to engage essential hydrogen bonding interactions with the binding site of the receptor coherently to what observed in different potent and selective hA 2A antagonists. Moreover, compounds of Series A have a phenyl or a 2-furyl ring at position 2, and an arylalkylamino moiety at position-5 because in many bicyclic derivatives of similar size and shape such groups afforded the best results in terms of hA 2A affinity and selectivity. P2Y4 is a purinergic receptor of the G protein-coupled receptor family. It is widely expressed in different tissues such as skin, gastrointestinal tract (GIT), heart, and central nervous system (CNS) (Burrell et al., Dermatol. 120, 440-447. 2003; Song et al., Purinergic Signalling, 7, 469-488. 2011 ). So far no selective ligand is known for this receptor subtype. Availability of such a ligand is essential not only for full pharmacological characterization of the receptor but also because of its possible pharmacotherapeutic impact. In the GIT, P2Y4 was shown to mediate chloride secretion by jejunalepithelium making the receptor a possible target for the treatment of cystic fibrosis and diarrhea (Robaye et al., Mol. Pharmacol., 63:777-783.2003) . It was also found to be involved in the regulation of amyloid precursor protein (APP) production and release in the brain. Since APP accumulation isassociated with the progression of Alzheimer's disease, P2Y4 receptors might be considered as potential pharmacotherapeutic targets for Alzheimer's disease (Tran M.D. Neurosci. Lett.. 492, 155-159. 2011) . In this context, a library of anthraquinone compounds, structurally related to reactive blue 2,were synthesized and investigated for their antagonistic activity at human P2Y4 receptors using a fluorescence-based calcium assay. Synthesis of these derivatives was possible througha microwave-assisted Cu0-catalyzed Ullmann coupling reaction of different 2-substituted 1-amino-4-bromoanthraquinones with aniline derivatives in phosphate buffer (Baqi, Y. and Müller, C.E. Org. Lett., 9, 1271 -1274 . 2007 Baqi, Y. and Müller, C.E. Nat. Protoc., 5, 945-953. 2010 ). The most active compound, sodium 1-amino-4-[4-(2-chlorophenylamino)-3-carboxyphenylamino]anthra quinone-2-sulfonate ( Fig. 1) , showed high inhibitory activity with an IC50 value of 0.067±0.02 μM. It exhibited selectivity against human P2Y1, P2Y2, and P2Y6 receptors with IC50values of 4.53±1.3 μM (P2Y1), 0.212±0.031 μM (P2Y2), and 0.675±0.138 μM (P2Y6), respectively. Analysis of structure-activity relationship of the synthesized compounds will be discuss Fig. 1 P2Y 2 is a G-protein-coupled receptor that has recently become a major research focus, owing to its apparent involvement in and proposed clinical significance for a range of different disorders, including osteoporosis, cancer, atherosclerosis, neurodegenerative and inflammatory diseases. The precise role of the P2Y 2 receptor in these conditions is often not clear, which can be partially attributed to the limited availability of potent and selective inhibitors that could be used for pharmacological studies. One of the most selective antagonists to date is AR-C118925 that has been developed by AstraZeneca. However, this compound is not commercially available and, as a result, is very vaguely described in the literature. We, therefore, re-synthesised AR-C118925 as well as two derivatives and assessed their inhibitory potential on P2Y 2 , further subtypes of the P2Y receptor family, P2X ion channels, adenosine receptors, as well as a range of other potential targets that complement the work of Kemp et al. The results obtained from this study constitute a significant contribution towards a comprehensive characterisation of this promising pharmacological tool and the synthesis scheme described here will facilitate access to this compound by other research groups. Adenosine receptor (ARs) ligands are considered useful therapeutic agents in a wide range of pathologies. In particular, A2A antagonists proved to be effective in the treatment of cerebral ischemia and in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases (PD) [Fredholm, B.B. et al. J. Pharmacol. Rev. 2011, 63, 1] . Balanced A1/A2A receptor antagonists also demonstrated efficacy in PD since they improve both motor (A2A) and cognitive (A1) impairments associated to the pathology [Mihara, T. et al. J. Pharmacol. Exp. Ther., 2007, 323, 708] . In the last few years we identified the pyrazolo [4,3-d] pyrimidin-7-amino scaffold to obtain potent human (h) AR antagonists (Series 1). Compounds of Series 1 showed nanomolar affinity and different degrees of selectivity for hARs, depending on the nature of the R5 and R2 substituents [Squarcialupi L. et al. J. Med. Chem. 2013, 52, 7640] . To shift affinity toward the hA2A receptor, various arylalkyl(amino) moieties were introduced at the 5 position (R5), while maintaining a phenyl ring at the 2-position. At this latter position, also the influence of arylmethyl or methyl residues was evaluated.
5.d Stable nucleotide analogues as potent GPR17 ligands
Preliminary results show that arylalkyl substituents or a 2-furyl ring at the 5-position, shift the affinity toward the A 2A and/or A 1 receptor. Molecular docking studies have been carried to rationalize the affinity data and to depict the hypothetical binding mode of these antagonists at hARs. (Adinolfi et al., 2012) . In the last years, several P2RX7 inhibitors have been developed and are actually in advanced stage trials for the therapy of inflammatory diseases. Here we suggest P2RX7 as target for antitumoral therapy. The aim of this study was to verify if systemic P2RX7 inhibition reduces tumoral growth in vivo both in human and in murine tumoral cell lines using xenograft and syngeneic mouse models, respectively. Tumors were obtained by subcutaneous injection of either B16 melanoma or ACN neuroblastoma cell lines in syngeneic mice (C57Bl/6) or in nude/nude mice, respectively. B16 and ACN tumoral growth was monitored for up to 14 and 33 day, respectively. C57Bl/6 and nude/nude mice were treated with PBS (placebo) or two different P2RX7 antagonists, A74003 or AZ10606120, every 2 days from 5th day post-inoculum. B16 derived tumors excised at day 14th showed a significantly reduced volume after treatment with both A74003 (10uM) or AZ10606120 (300 nM) (~½ and~¼ compared to placebo, respectively). The decreased tumoral growth caused by P2RX7 inhibition was significantly different from day 9th post inoculum both for A74003 and AZ10606120 treatment groups. ACN derived tumors excised at day 33rd showed a significantly reduced volume after treatment with both A74003 (5 uM) and AZ10606120 (300 nM) (~¾ compared to placebo). Although not significantly different, a trend of reduction of tumoral growth, following P2RX7 inhibition, was also appreciable during in vivo measurement.
In conclusion, present data show for the first time that systemic inhibition of P2RX7 affects tumoral growth both in murine and in human tumoral cell lines indicating the involvement of P2RX7 in cancer development. In this view it is convincible to identify P2RX7 as therapeutical target in cancer. To P2X7 receptor a role in bone formation and resorption has been assigned since the first studies on receptor knock out mice. Both osteoblast proliferation and osteoclast activation and fusion have been demonstrated to be related to P2X7 receptor. These data have been further supported by findings correlating P2X7 single nucleotide polymorphisms (SNPs) and osteoporosis. P2X7 has been shown to be involved also in tumour formation, growth and neovascularisation, and expressed in different tumour types (Adinolfi E. et al. Cancer Res.72(12):2957 -69. 2012 ). Although P2X7 function in bonerelated cancer has been recently reviewed (Adinolfi E. et al. J. Osteoporosis; 637863, 2012) , further insights into P2X7 contribution to osteosarcoma biology are still requested. Nine different naturally occurring splice variants of the receptor are actually known. Among them, P2X7A is the wellcharacterized full-length isoform. Depending on the dose of the agonist, P2X7A is able to form both a plasma membrane channel for small cations, and a larger pore, permeable to solutes of molecular weight up to 900 kDa. Conversely, P2X7B is a shorter isoform, widely expressed in human tissues, only capable to generate the membrane channel. The present study was dedicated to investigate a possible role of P2X7 and its main splice variants in human osteosarcoma and in related osteoblastic activity. A tissue array containing 59 different osteosarcoma samples was tested at immunohistochemistry using an anti-P2X7 antibody: all tumours stained positively with some difference depending on the osteosarcoma type. Moreover, the human osteosarcoma cell line Te85, not expressing the receptor, has been transfected with the two main hP2X7 splice variants, either separately (Te85-P2X7A and Te85-P2X7B), or jointly (Te85-P2X7A + B). P2X7 expression and function in transfected cells have been assessed at different levels including mRNA, plasma membrane and cytosolic Ca 2+ increase. As previously shown in another cell model, (Adinolfi E. Et al. FASEB J. 24(9) :3393-404. 2010) co-transfection with P2X7A + B resulted in potentiated responses. P2X7 expression conferred a proliferative advantage in absence of serum, the highest proliferative activity being that of Te85-P2X7B cells. NFATc1 (Nuclear factor of activated T lymphocytes) activity, that is a marker of osteoblast proliferation, resulted increased in all P2X7-transfected cells. Addressing our attention to osteoblast activity, we found that Te85-P2X7B cells showed reduced osteodeposition. Accordingly, also alkaline phosphatase activity in these cells was the lowest among all P2X7-transfected cells. Finally, a significant reduction of mRNA RANK-L levels was found in all P2X7-transfected cells, particularly in the Te85-P2X7B cells. These results show that osteosarcomas express P2X7 receptor at high levels and that the receptor might contribute to bone mass increase in osteoblastic malignant lesions. 
